

# Effects of resistance exercise and whey protein supplementation on skeletal muscle strength, mass, physical function, and hormonal and inflammatory biomarkers in healthy active older men: a randomised, double-blind, placebo-controlled trial

Corbin Griffen, Michael Duncan, John Hattersley, Martin O. Weickert, Alexander Dallaway, and Derek Renshaw

**Author post-print (accepted) deposited by Coventry University's Repository**

## **Original citation & hyperlink:**

Griffen, C., Duncan, M., Hattersley, J., Weickert, M.O., Dallaway, A. and Renshaw, D., 2022. Effects of resistance exercise and whey protein supplementation on skeletal muscle strength, mass, physical function, and hormonal and inflammatory biomarkers in healthy active older men: a randomised, double-blind, placebo-controlled trial. *Experimental gerontology*, 158, 111651.

<https://doi.org/10.1016/j.exger.2021.111651>

DOI [10.1016/j.exger.2021.111651](https://doi.org/10.1016/j.exger.2021.111651)

ISSN 0531-5565

Publisher: Elsevier

© 2022, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

<http://creativecommons.org/licenses/by-nc-nd/4.0/>

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

This document is the author's post-print version, incorporating any revisions agreed during the peer-review process. Some differences between the published version and this version may remain and you are advised to consult the published version if you wish to cite from it.

1 **Title: Effects of resistance exercise and whey protein supplementation on skeletal**  
2 **muscle strength, mass, physical function, and hormonal and inflammatory**  
3 **biomarkers in healthy active older men: a randomised, double-blind, placebo-**  
4 **controlled trial**

5  
6 **Authors:** Griffen, C.<sup>\*1,2</sup>, Duncan, M.<sup>1,3</sup>, Hattersley, J.<sup>1,2,4</sup>, Weickert, M. O.<sup>1,5,6</sup>, Dallaway, A.<sup>1,2</sup>,  
7 and Renshaw, D.<sup>1</sup>

8  
9 **Affiliations:** <sup>1</sup>Centre for Sport, Exercise and Life Sciences, Research Institute of Health and  
10 Wellbeing, Coventry University, Coventry, CV1 2DS, United Kingdom; <sup>2</sup>Human Metabolism  
11 Research Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2  
12 2DX, United Kingdom; <sup>3</sup>School of Life Sciences, Faculty of Health and Life Sciences,  
13 Coventry University, Coventry, CV1 2DS, United Kingdom; <sup>4</sup>School of Engineering,  
14 University of Warwick, Coventry, CV4 7HL, United Kingdom; <sup>5</sup>Department of Endocrinology  
15 and Diabetes, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2  
16 2DX, United Kingdom; <sup>6</sup>Warwick Medical School, University of Warwick, Coventry, United  
17 Kingdom

18  
19 \* Corresponding author: Corbin Griffen, griffenc@uni.coventry.ac.uk

20 **Number of figures:** 7

21 **Number of tables:** 5

22  
23 **Running title:** Resistance training and protein in older men  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Abbreviations**

38 1RM, one repetition maximum

39 6MWT, 6-min walk test

40 CRP, C-reactive protein

41 CONSORT, Consolidated Standards of Reporting Trials

42 eGFR, estimated glomerular filtration rate

43 ELISA, enzyme-linked immunosorbent assay

44 EWGSOP, European Working Group of Sarcopenia in Older People

45 FFM, fat-free mass

46 IGF-1, insulin-like growth factor 1

47 IL-6, interleukin-6

48 IL-10, interleukin-10

49 MPS, muscle protein synthesis

50 RCT, randomised controlled trial

51 RDA, recommended dietary allowance

52 RE, resistance exercise

53 SPPB, short physical performance battery

54 SMM, skeletal muscle mass

55 TNF- $\alpha$ , tumor necrosis factor-alpha

56

57

58

59

60

61

62

63

64

65 **Abstract**

66 **Purpose:** To determine the individual and combined effects of 12 weeks of resistance  
67 exercise (RE) and whey protein supplementation on skeletal muscle strength (primary  
68 outcome), mass and physical function, and hormonal and inflammatory biomarkers in older  
69 adults.

70 **Methods:** Thirty-six healthy older men [(mean  $\pm$  SE) age:  $67 \pm 1$  y; BMI:  $25.5 \pm 0.4$  kg/m<sup>2</sup>]  
71 were randomised to either control (CON;  $n = 9$ ), whey protein (PRO;  $n = 9$ ), RE + control  
72 (EX+CON;  $n = 9$ ), or RE + whey protein (EX+PRO;  $n = 9$ ) in a double-blinded fashion. Whole-  
73 body RE (2 sets of 8 repetitions and 1 set to volitional failure at 80% 1RM) was performed  
74 twice weekly. Supplements (PRO, 25 g whey protein isolate; CON, 23.75 g maltodextrin) were  
75 consumed twice daily.

76 **Results:** EX+CON and EX+PRO increased leg extension ( $+19 \pm 3$  kg and  $+20 \pm 3$  kg,  
77 respectively) and leg press 1RM ( $+27 \pm 3$  kg and  $+39 \pm 2$  kg, respectively) greater than the  
78 CON and PRO groups ( $P < 0.001$ , Cohen's  $d = 1.50-1.90$ ). RE (EX+CON and EX+PRO groups  
79 pooled) also increased fat-free mass (FFM) ( $+0.9 \pm 0.3$  kg) and 6-min walk test distance ( $+21$   
80  $\pm 5$  m) and decreased fat mass ( $-0.4 \pm 0.4$  kg), and interleukin-6 ( $-1.0 \pm 0.4$  pg/mL) and tumor  
81 necrosis factor-alpha concentration ( $-0.7 \pm 0.3$  pg/mL) greater than non-exercise (CON and  
82 PRO groups pooled;  $P < 0.05$ , Cohen's  $f = 0.37-0.45$ ). Whey protein supplementation (PRO  
83 and EX+PRO groups pooled) increased 4-m gait speed greater than control (CON and  
84 EX+CON groups pooled) ( $+0.08 \pm 0.03$  m/s;  $P = 0.007$ ,  $f = 0.51$ ).

85 **Conclusion:** RE increased muscle strength, FFM and physical function, and decreased  
86 markers of systemic inflammation in healthy active older men. Whey protein  
87 supplementation alone increased gait speed. No synergistic effects were observed.

88

89 **Key words:** ageing, resistance exercise, whey protein, sarcopenia, systemic inflammation

90

91

92

93 **1. Introduction**

94 Age-related declines in skeletal muscle mass (SMM), strength, and physical function, termed  
95 sarcopenia (Cruz-Jentoft et al., 2019), progress at rates of ~0.5-1%, ~1-3%, and ~0.5% per  
96 annum, respectively, manifesting around the fifth decade of life (Clark and Manini, 2008; Daly  
97 et al., 2013; Janssen, 2010). Sarcopenia is associated with various adverse health outcomes,  
98 including an increased risk of falls and fractures, reduced physical function (Beaudart et al.,  
99 2017), and greater cardiovascular, metabolic disease and mortality risk (Bahat and Ilhan,  
100 2016; de Buysse et al., 2016; Hunter et al., 2019). In economic terms, in the United Kingdom,  
101 the annual cost associated with muscle weakness is estimated at £2.5 billion (Pinedo-  
102 Villanueva et al., 2019). Hence, interventions that attenuate sarcopenia are imperative.

103

104 Resistance exercise (RE) is an effective stimulus to increase muscle strength (Peterson et al.,  
105 2010), fat-free mass (FFM) (Peterson et al., 2011), and physical function (Yoshimura et al.,  
106 2017). Meta-analyses also suggest that increased dietary protein intake may augment the  
107 adaptive response of skeletal muscle to RE (Cermak et al., 2012; Finger et al., 2015; Kirwan  
108 et al., 2021; Liao et al., 2017; Morton et al., 2018). However, whilst several individual studies  
109 in older adults have demonstrated greater increases in muscle strength, skeletal muscle  
110 and/or FFM, and physical function following combined RE and increased dietary protein intake  
111 compared to RE alone (Bell et al., 2017; Daly et al., 2014; Huschtscha et al., 2021; Junior et  
112 al., 2018; Kang et al., 2019; Rondanelli et al., 2020, 2016; Tieland et al., 2012b; Verreijen et  
113 al., 2015; Yamada et al., 2019; Zdzieblik et al., 2015), the majority of studies have not  
114 observed such effects (Arnarson et al., 2013; Candow et al., 2006; Chalé et al., 2013; de  
115 Carvalho Bastone et al., 2020; Dulac et al., 2020; Englund et al., 2018; Fielding et al., 2017;  
116 Gryson et al., 2014; Hofmann et al., 2016; Holm et al., 2008; Holwerda et al., 2018; Kim et al.,  
117 2012; Kirk et al., 2020, 2019; Krause et al., 2019; Kukuljan et al., 2009; Leenders et al., 2013;  
118 Maesta et al., 2007; Maltais et al., 2016; Oesen et al., 2015; Ottestad et al., 2017; Shahar et  
119 al., 2013; Thomson et al., 2016; Verdijk et al., 2009; Verreijen et al., 2017).

120

121 Inconsistent findings may be explained by the population studied, habitual protein intake of  
122 participants, and characteristics of the protein intervention. To explain the latter, several  
123 studies that observed synergistic effects evaluated a multi-ingredient supplement, which  
124 contained nutrients such as vitamin D, creatine and fatty acids in addition to protein that may  
125 have contributed to the augmented effect (Bell et al., 2017; Rondanelli et al., 2020, 2016;  
126 Verreijen et al., 2015; Yamada et al., 2019). Furthermore, studies in healthy older adults that  
127 observed synergistic effects increased dietary protein intake by 0.5-0.6 g/kg/d (Bell et al.,  
128 2017; Huschtscha et al., 2021; Junior et al., 2018), which exceeds the proposed increase  
129 required to elicit gains in SMM ( $\geq 0.4$  g/kg/d) (Moore et al., 2015; Park et al., 2018). In contrast,  
130 studies that failed to observe amplified effects increased dietary protein intake by  $\leq 0.3$  g/kg/d  
131 (Arnarson et al., 2013; Dulac et al., 2020; Gryson et al., 2014; Hofmann et al., 2016; Holwerda  
132 et al., 2018; Kirk et al., 2020, 2019; Kukuljan et al., 2009; Leenders et al., 2013; Maesta et al.,  
133 2007; Maltais et al., 2016; Verdijk et al., 2009).

134  
135 Moreover, a meta-regression conducted by Morton et al. (2018) showed, whilst driven by data  
136 in young adults, that  $\sim 1.6$  g protein/kg/d might be required to maximally augment RE-induced  
137 gains in FFM in healthy adults. In support, protein intakes up to 1.6 g/kg/d [twice the  
138 recommended dietary allowance (RDA)] have also been recommended and established to  
139 mitigate sarcopenia (Mitchell et al., 2017; Morley et al., 2010). However, this level of dietary  
140 protein intake was only achieved by two of the aforementioned studies (Bell et al., 2017;  
141 Huschtscha et al., 2021). Additionally, the protein intervention employed by Huschtscha et al.  
142 (2021) elicited an evenly distributed dietary protein intake of  $>0.4$  g/kg/meal (at breakfast,  
143 lunch, and dinner), the reported dose required to maximally stimulate rates of muscle protein  
144 synthesis (MPS) (Moore et al., 2015) and has been associated with increased muscle strength  
145 (Loenneke et al., 2016) and physical function (ten Haaf et al., 2018) in older adults. Taken  
146 together, current evidence suggests that an increase of  $\geq 0.4$  g protein/kg/d and a total protein  
147 intake of  $\sim 1.6$  g/kg/d, which is evenly distributed across all three main meals ( $>0.4$  g/kg/meal),

148 may be required to amplify RE-induced effects on sarcopenia outcomes in healthy older  
149 adults.

150

151 A limitation of most studies investigating the synergistic effects of RE and increased dietary  
152 protein intake on sarcopenia outcomes was the failure to include a protein only group. Of the  
153 studies [excluding Huschtscha et al. (2021)] that examined the synergistic effects compared  
154 to both RE and increased dietary protein alone (de Carvalho Bastone et al., 2020; Gryson et  
155 al., 2014; Huschtscha et al., 2021; Kim et al., 2012; Kirk et al., 2020; Krause et al., 2019;  
156 Kukuljan et al., 2009; Maesta et al., 2007; Shahar et al., 2013; Verreijen et al., 2017), the  
157 increase and daily dose of dietary protein intake ( $\leq 0.3$  g/kg/d and  $< 1.6$  g/kg/d, respectively)  
158 was suboptimal according to previously mentioned data (Moore et al., 2015; Morton et al.,  
159 2018; Park et al., 2018). However, whilst Huschtscha et al. (2021) increased dietary protein  
160 intake by  $> 0.4$  g/kg/d to  $\geq 1.6$  g/kg/d, this study did not employ a double-blind, placebo-  
161 controlled design, which has been recommended for trials investigating the effectiveness of  
162 interventions to treat or prevent sarcopenia by an expert working group (Reginster et al.,  
163 2016). Lack of such experimental control significantly increased the risk of bias in this study.  
164 Consequently, to our knowledge, data on the synergistic effects compared to each intervention  
165 alone employing a double-blind, placebo-controlled design and utilising the optimal dietary  
166 protein regimen is currently unavailable, highlighting the need for further robustly designed  
167 studies.

168

169 Several physiological factors are involved in the pathogenesis of sarcopenia. These include,  
170 but are not limited to, chronic systemic inflammation [e.g., elevated interleukin (IL)-6, C-  
171 reactive protein (CRP) and tumor necrosis factor-alpha (TNF- $\alpha$ ), and reduced IL-10] and  
172 changes in the hormonal milieu [e.g., reduced insulin-like growth factor 1 (IGF-1), flattened  
173 diurnal cortisol secretion, and increased myostatin] (Beyer et al., 2012; McKee and Morley,  
174 2019; White and Lebrasseur, 2014). Previous work has shown that RE and increased dietary  
175 protein intake independently decrease markers of systemic inflammation (Lieberman et al.,

176 2019; Sardeli et al., 2018) and increase IGF-1 (Bauer et al., 2015; Bo et al., 2019; Jiang et al.,  
177 2020) in older adults. Others have also demonstrated decreases in fasting concentrations of  
178 cortisol (Häkkinen et al., 2002; Izquierdo et al., 2003) and myostatin (Bagheri et al., 2020,  
179 2019) following RE. However, there is currently limited evidence of the combined effects of  
180 these interventions on these biomarkers compared to each intervention alone in older adults.  
181 Such data may identify mechanisms which explain the synergistic sarcopenic-mitigating  
182 effects.

183

184 The primary aim of the present study was to investigate the individual and combined effects  
185 of RE and whey protein supplementation [aimed to increase dietary protein intake by  $\geq 0.4$   
186 g/kg/d to  $\sim 1.6$  g/kg/d ( $>0.4$  g/kg/meal)] using a double-blind, placebo-controlled design, on  
187 muscle strength in healthy active older men. Secondary aims were to examine the effects on  
188 other sarcopenia outcomes (i.e., skeletal muscle/FFM and physical function) and multiple  
189 hormonal and inflammatory biomarkers associated with sarcopenia, and to determine whether  
190 changes correlate with changes in sarcopenia outcomes. We hypothesised that RE combined  
191 with whey protein supplementation would augment the effects on SMM, strength and physical  
192 function and elicit a superior systemic hormonal and inflammatory profile compared to each  
193 intervention alone. We also postulated that changes in sarcopenia outcomes would correlate  
194 with changes in hormonal and inflammatory biomarkers.

195

## 196 **2. Materials and methods**

197

### 198 *2.1 Participants*

199 Thirty-six healthy, community-dwelling older men (mean  $\pm$  SE age:  $67 \pm 1$  y) participated in  
200 this study. The following eligibility criteria applied: i) aged 60-80 y; ii) BMI between 18.5 and  
201  $30 \text{ kg/m}^2$ ; iii) non-smoker; iv) weight stable ( $\pm < 3$  kg change in the previous 6 months); v) no  
202 participation in RE in the previous 6 months; vi) no past or existing history of cancer, diabetes  
203 mellitus, or cardiovascular, thyroid, or renal disease; and vii) not taking statins, or non-steroidal



204 anti-inflammatory or metabolism-affecting drugs. Participants were recruited from Coventry,  
205 UK, and surrounding areas by newspaper advertisements, contact with local groups and  
206 organisations, and via word of mouth. The study was approved by Coventry University Ethics  
207 Committee (project code: P59723), registered at [clinicaltrials.gov](https://clinicaltrials.gov) as NCT03299972, and is  
208 reported in accordance with Consolidated Standards of Reporting Trials (CONSORT)  
209 guidelines (Schulz et al., 2010). All participants provided written informed consent in  
210 accordance with the Declaration of Helsinki.

211

## 212 *2.2 Experimental design*

213 This was a 12-week randomised, controlled, double-blind, 4-arm parallel group trial, which  
214 was conducted between October 2017 and May 2019. Participants were randomised to either  
215 control (CON;  $n = 9$ ), whey protein (PRO;  $n = 9$ ), RE + control (EX+CON;  $n = 9$ ), or RE + whey  
216 protein (EX+PRO;  $n = 9$ ). A coded (A, B, C or D) randomisation scheme was used.  
217 Randomisation was performed using the minimization allocation method, with stratification for  
218 age and body mass index (BMI) using free online software (QMinim; <http://rct.mui.ac.ir/q/>). A  
219 key to the randomisation code was held by an investigator who was not directly involved with  
220 participant recruitment, exercise training, or testing. All measurements were taken at baseline  
221 and following the 12-week intervention. A schematic of the trial design can be seen in Fig. 1.  
222 To minimise diurnal variation, muscle strength, body composition, and physical function  
223 measures were performed at the same time of day ( $\pm 1$  h) at both testing sessions. In addition  
224 to the main analysis, exploratory analyses were also conducted between pooled exercise  
225 (EX+CON and EX+PRO groups;  $n = 18$ ) and non-exercise groups (CON and PRO groups;  $n$   
226 = 18), and between pooled whey protein (PRO and EX+PRO groups;  $n = 18$ ) and control  
227 supplement groups (CON and EX+CON groups;  $n = 18$ ).



241 consisted of a 5-min warm up on a cycle ergometer at a self-selected cadence, followed by 3  
242 sets of leg press, lateral row, hamstring curl, chest press, leg extension and shoulder press  
243 (in that order) on fixed RE machines (Life Fitness, Rosemont, Illinois, USA). These exercises  
244 were chosen to target major muscle groups using multi-joint movements to stimulate whole-  
245 body increases in SMM and strength and to improve physical function (Fragala et al., 2019).  
246 During the first 4 weeks of training, RE load began at 60% one repetition maximum (1RM)  
247 (10-12 repetitions per set) and was gradually increased by ~5-7% per week to 80% 1RM (8  
248 repetitions per set), where it remained until the end of the intervention. Training volume was  
249 selected based on meta-analyses which suggest that 2-3 sets per exercise and ~8 repetitions  
250 per set elicits superior increases in muscle hypertrophy and strength in older adults (Borde et  
251 al., 2015; Peterson et al., 2010). Exercise load was chosen based on meta-analyses which  
252 suggest for optimisation of muscle strength, which is considered the primary index of  
253 sarcopenia by the European Working Group of Sarcopenia in Older People (EWGSOP) (Cruz-  
254 Jentoft et al., 2019), high-load RE (~70-80% 1RM) elicits the largest effects (Borde et al.,  
255 2015; Steib et al., 2010). The final set of each exercise was performed to volitional failure,  
256 which was defined as the inability to perform an additional repetition with the correct form.  
257 Completion of repetitions was monitored during each session. Participants were allocated 60  
258 s and 3 min recovery between sets and exercises, respectively. Exercise load was adjusted  
259 according to 1RM tests performed every 4 weeks to mimic typical changes in muscle fibre  
260 type and strength (Kraemer and Ratamess, 2004) and when participants were able to  
261 complete >12 repetitions on the final set of each exercise. Sessions concluded with a 5-min  
262 cool-down on a cycle ergometer. Compliance was monitored using a training log.

263

#### 264 *2.4 Nutritional supplements*

265 Participants ingested either 25 g whey protein isolate (including ~3 g leucine) (Instantized  
266 BiPRO; Agropur, Quebec, Canada) or an energy-matched control (23.75 g maltodextrin;  
267 Myprotein, Northwich, UK) twice daily, consumed directly after breakfast and lunch. On RE  
268 training days, participants in the EX+CON and EX+PRO groups consumed their second

269 supplement immediately following the session. The nutritional composition of the experimental  
270 supplements can be seen in Table 1. Supplements were unflavoured, similar in powder  
271 weight, and were provided in opaque sachets in a double-blinded manner (Flexible Packaging  
272 Services Ltd, Wirral, UK). Participants were instructed to dissolve the contents of their  
273 supplements into ~200 mL of water combined with a no-added sugar cordial of choice  
274 immediately prior to consumption using a handheld shaker (Myprotein, Northwich, UK).  
275 Flexibility in cordial use was provided to mitigate flavour fatigue. Compliance was assessed  
276 by the number of empty sachets returned by participants at the end of the study and through  
277 the use of a supplementation log. To test the success of supplement blinding, participants  
278 completed an exit questionnaire on completion of the study.

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297 **Table 1** Nutritional composition of the experimental supplements (per serving)<sup>1</sup>

Component	Whey protein isolate (PRO) <sup>1</sup>	Control (CON)
	25 g	23.75 g
Energy (kcal)	95	95
Carbohydrate (g)	0	23.75
Protein (g)	22.8	0
<b><u>EAA (g)</u></b>	11.1	0
<i>Histidine (g)</i>	0.5	0
<i>Lysine (g)</i>	2.2	0
<i>Methionine (g)</i>	0.4	0
<i>Phenylalanine (g)</i>	0.8	0
<i>Threonine (g)</i>	1.1	0
<i>Tryptophan (g)</i>	0.7	0
<b><u>BCAA (g)</u></b>	5.4	0
<i>Leucine (g)</i>	2.9	0
<i>Isoleucine (g)</i>	1.3	0
<i>Valine (g)</i>	1.2	0
<b><u>NEAA (g)</u></b>	11.7	0
<i>Alanine (g)</i>	1.0	0
<i>Arginine (g)</i>	0.5	0
<i>Aspartic Acid/Asparagine (g)</i>	2.5	0
<i>Cysteine (g)</i>	0.6	0
<i>Glutamic Acid/Glutamine (g)</i>	3.6	0
<i>Glycine (g)</i>	0.4	0
<i>Proline (g)</i>	1.1	0
<i>Serine (g)</i>	0.8	0
<i>Tyrosine (g)</i>	0.8	0
Fat (g)	0.4	0

298

299 <sup>1</sup>Whey protein isolate also contained per serving: vitamin A (<25 IU), vitamin C (<0.5 mg),  
 300 vitamin D (0.2 µg), iron (0.25 mg), calcium (21.3 mg), phosphorus (85 mg), magnesium (2.5  
 301 mg) chloride (20 mg), sodium (172.5 mg), potassium (17.5 mg). BCAA, branched-chain amino  
 302 acids; EAA, essential amino acids; NEAA, non-essential amino acids.

303

304 The whey protein dosing regimen employed was chosen based on previous studies that have  
 305 demonstrated that older adults typically consume insufficient amounts of dietary protein at

306 breakfast and lunch to maximally stimulate rates of MPS (~0.2 and ~0.3 g/kg, respectively  
307 (Farsijani et al., 2017; Smeuninx et al., 2020; Tieland et al., 2012a). Based on a hypothesised  
308 habitual protein intake of ~1.0 g/kg/d and a mean body mass of ~80 kg of the cohort in this  
309 study to that of others (Bell et al., 2017; Kirk et al., 2019; Smeuninx et al., 2020), 25 g of whey  
310 protein (~0.25 g protein/kg) at breakfast and lunch was postulated to yield a daily protein  
311 distribution of ~0.45 g/kg, ~0.55 g/kg, and ~0.5 g/kg at breakfast, lunch and dinner,  
312 respectively. Thus, meeting the per meal protein ( $\geq 0.4$  g/kg) and leucine ( $\geq 2.5$  g) thresholds  
313 required to maximally stimulate rates of MPS in older adults (Moore et al., 2015). In addition,  
314 it was hypothesised that the whey protein dosing regimen would increase daily dietary protein  
315 intake from ~1.0 to 1.6 g/kg/d, the intake recommended to curb sarcopenia (Phillips et al.,  
316 2016) and maximise SMM accretion during RE training (Morton et al., 2018), whilst also  
317 surpassing the suggested required increase of  $\geq 0.4$  g/kg/d to stimulate gains in SMM in  
318 healthy older adults (Park et al., 2018).

319

### 320 *2.5 Dietary intake and habitual physical activity*

321 Participants completed a 3-day diet diary (2 weekdays and 1 weekend day) at baseline (prior  
322 to commencing the intervention) and during weeks 6 and 12. Dietary records were analysed  
323 using dietary analysis software (Nutritics Version 5.097; Nutritics, Dublin, Ireland). To control  
324 for changes in habitual physical activity levels/intensity during waking hours [i.e., step count  
325 and time spent sedentary, and in light and moderate-vigorous physical activity (MVPA)],  
326 participants wore a tri-axial accelerometer on the dominant wrist for 7 days at baseline and  
327 week 12 (Freedson et al., 1998). The accelerometer was sampled at 80 Hz and analysed in  
328 60-s EPOCHs. Participants were instructed to not alter their habitual diet or physical activity  
329 levels for the duration of the study.

330

### 331 *2.6 Muscle strength*

332 Muscle strength (primary outcome) was assessed by 1RM tests on the leg press and leg  
333 extension machines (in that order) (Life Fitness, Rosemont, Illinois, USA) using the guidelines

334 of Kraemer et al. (2006). Prior to baseline testing, proper lifting technique was demonstrated  
335 and practiced by participants to minimise a potential learning effect (Levinger et al., 2009;  
336 Phillips et al., 2004). During 1RM testing, participants first completed 5-10 repetitions at 40-  
337 60% of perceived 1RM followed by 3-5 repetitions at 60-80% of perceived 1RM. The load was  
338 then gradually increased by 5-10%, and participants performed one repetition at each  
339 increased load until they were unable to achieve a complete repetition. One repetition  
340 maximum was determined as the last successful lift prior to failure. Three min rest was  
341 allocated between each maximal lift. Handgrip strength was measured using a JAMAR  
342 hydraulic handgrip dynamometer (Jamar 5030J1; Sammons Preston, Bolingbrook, Illinois,  
343 USA) using standardised procedures (Roberts et al., 2011).

344

#### 345 *2.7 Body composition*

346 Body composition (SMM, FFM and fat mass) was measured in the morning by bioelectrical  
347 impedance analysis (BIA) (BC-418 MA; Tanita Corporation, Tokyo, Japan). Skeletal muscle  
348 mass was estimated using the formula of Janssen et al. (2000). This method has been cross-  
349 validated against magnetic resonance imaging for measurement of SMM in older adults  
350 (Janssen et al., 2000). Skeletal muscle and fat mass index ( $\text{kg}/\text{m}^2$ ) were calculated by dividing  
351 SMM and FM by height squared, respectively. Waist circumference was measured at the  
352 midpoint between the lowest rib margin and the iliac crest. Hip circumference was measured  
353 at the widest portion of the hips. Both outcomes were measured to the nearest 0.1 cm using  
354 a measuring tape (Seca 201; Seca GmbH, Hamburg, Germany).

355

#### 356 *2.8 Physical function*

357 Physical function was assessed by the short physical performance battery (SPPB) and the 6-  
358 min walk test (6MWT). The SPPB followed standard procedures, which consisted of three  
359 timed tests: 4-m gait speed, time to perform five chair raises, and standing balance (feet  
360 together, semi-tandem and tandem) (Guralnik et al., 2000). Each test was scored equally  
361 between 0 and 4. The total score between 0 and 12 was used for analysis. The 6MWT was

362 performed adhering to guidelines set by the American Thoracic Society (Crapo et al., 2002).  
363 A 30 m indoor track was marked out with cones at either end. Participants were informed that  
364 the aim of the test was to cover as much distance as possible in six minutes.

365

### 366 *2.9 Biochemical analysis*

367 Venous blood was collected at 0815 h following a >10 h overnight (observed) fast and >72 h  
368 following the final RE session to allow for biomarkers to return to basal levels (Schoenfeld,  
369 2012). Whole blood was collected into ethylenediaminetetraacetic acid (EDTA), heparin and  
370 serum separator tube (SST) vacutainers (BD 3 mL vacutainers; BD, New Jersey, USA) then  
371 immediately centrifuged at 1900 x g for 10 min at 4°C (Eppendorf 5702R; Eppendorf UK Ltd,  
372 Stevenage, UK). Serum samples were rested for 30 min prior to centrifugation to allow for  
373 sufficient clotting. Aliquots containing plasma and serum were stored at -80°C until analysis.  
374 Due to difficulty in blood collection, blood was unable to be drawn from two participants ( $n = 1$   
375 participant in the CON and EX+CON groups). Therefore,  $n = 34$  participants had full blood  
376 data. Commercially available enzyme-linked immunosorbent assay (ELISA)'s were used to  
377 detect and quantify concentrations of plasma IL-6 (Item # D6050 and HS600C), IL-10 (Item #  
378 HS100C), TNF- $\alpha$  (Item # HSTA00E) and CRP (Item # DCRP00), serum IGF-1 (Item #  
379 DB100B) and myostatin (Item # DGDF80) (R&D Systems Inc., Abingdon, UK), and plasma  
380 annexin A1 (Item # ab222868; Abcam, Cambridge, UK) and insulin (Item # EIA-2935; DRG  
381 Instruments GmbH, Marburg, Germany). Serum creatinine was determined using an  
382 enzymatic method on an automated clinical chemistry analyser (Cobas c720 analyser, Roche,  
383 Mannheim, Germany). Estimated glomerular filtration rate (eGFR) was calculated using the  
384 Modification of Diet in Renal Disease (MDRD) equation (Levey et al., 2006).

385

386 Saliva samples were collected whilst participants ( $n = 33$ ) resided in respiration chambers for  
387 24 h under highly controlled conditions, as described in Supplementary Materials. Samples  
388 were collected immediately upon waking at 0650 h, and at 0805 h, 1225 h, 1700 h, and 2000  
389 h using a synthetic swab (Salivette; Sarstedt, Nümbrecht, Germany). Samples were



390 centrifuged at 1900 x g for 2 min and stored at -80°C until analysis. Saliva samples were  
391 analysed for cortisol by ELISA (Item # 1-3002; Salimetrics, Pennsylvania, USA). Salivary  
392 cortisol data was used to calculate multiple indices. Firstly, all five samples were used to  
393 calculate salivary cortisol area under the curve (AUC) (nmol/L x 790 min) using the trapezoidal  
394 method. Secondly, salivary cortisol concentration upon waking (0650 h) and in the evening  
395 (2000 h) are reported as separate indices. Lastly, salivary cortisol slope (peak-to-evening)  
396 was calculated as the rate of salivary cortisol change from peak morning (0650 or 0805 h,  
397 depending on the highest concentration) to 2000 h (Adam et al., 2017). Cortisol was measured  
398 as it plays a key role in influencing metabolic functions, including gluconeogenesis, glycogenolysis  
399 and proteolysis (Coderre et al., 1991; Simmons et al., 1984). Diurnal salivary cortisol and elevated  
400 evening (2000 h) cortisol concentration have also been associated with sarcopenia (Gonzalez  
401 et al., 2018; Rodriguez et al., 2021), and a limitation of previous studies assessing cortisol  
402 following RE and increased dietary protein intake in older adults was the sole measurement of  
403 fasting cortisol (Häkkinen et al., 2002; Huschtscha et al., 2021; Izquierdo et al., 2003; Park et  
404 al., 2019). The intra-assay CVs were 9.5%, 9.8%, 11.8%, 2.7%, 9.9%, 9.9%, 9.1%, 4.2%,  
405 7.7% and 9.0% for plasma insulin, IL-6, high sensitivity IL-6, IL-10, TNF- $\alpha$ , CRP and annexin  
406 A1, serum IGF-1 and myostatin, and salivary cortisol, respectively.

407

## 408 *2.10 Statistical analysis*

409 Based on change in muscle strength from previously published data in older adults following  
410 12 weeks of RE and oral protein supplementation (Esmarck et al., 2001), an *a priori* power  
411 calculation using G\*Power (Version 3.1.9.2; Dusseldorf, Germany) for a repeated measures  
412 ANCOVA with one covariate indicated a minimum of 36 participants ( $n = 9$  per group) were  
413 required to observe a significant group-by-time interaction on 1RM strength measures [ $\alpha =$   
414 0.05;  $\beta = 0.8$ ; effect size (Cohen's  $f$ ) = 0.6].

415

416 Statistical analysis was performed using SPSS version 25 (IBM Corporation, New York, USA).  
417 Data are presented as means  $\pm$  SE (data on mean difference  $\pm$  SD between groups is also

418 reported in supplementary materials). All data were checked for normality using the Shapiro-  
419 Wilk test. Non-parametric data were transformed using appropriate transformation (i.e., log,  
420 square root, or reciprocal). When transformation was unsuccessful, non-parametric tests were  
421 utilised. Participant baseline characteristics were analysed by one-way ANOVA. A mixed-  
422 model ANCOVA with time as the within-subjects factor, group as the between-subjects factor,  
423 and respective baseline values as covariates was conducted to determine group-by-time  
424 interactions. Following significant group-by-time interactions, significant between-group  
425 differences were identified using post-hoc tests with a Bonferroni correction for multiple  
426 comparisons. For exploratory analyses comparing pooled groups (i.e., exercise and non-  
427 exercise groups, and whey protein and control groups), supplement consumed and RE  
428 participation were also controlled for in the ANCOVA model, respectively. Non-parametric data  
429 were analysed using the Scheirer-Ray-Hare two-way ANOVA of ranks test (including baseline  
430 rank as a covariate) with post-hoc analysis conducted using the Mann-Whitney U test.  
431 Longitudinal changes within groups were analysed using 2-tailed paired samples *t*-tests.  
432 Correlations between changes in SMM, strength and physical function and changes in  
433 hormonal and inflammatory biomarkers were analysed by partial correlation controlled for  
434 intervention group (Pearson's for parametric data and Spearman's rank order coefficients for  
435 non-parametric data). Significance was set at  $P < 0.05$ . Effect sizes were calculated for *t*-  
436 (Cohen's *d*) and F tests (Cohen's *f*) to quantify the magnitude of change (within and between  
437 groups) using previously published formulae (Cohen, 1988). The standard definitions of  
438 Cohen's *d* are: very small, 0.01-0.19; small, 0.20-0.49; medium, 0.50-0.79; large, 0.80-1.29;  
439 and very large,  $\geq 1.20$  (Cohen, 1988; Sawilowsky, 2009). The standard definitions of Cohen's  
440 *f* are: small, 0.10; medium, 0.25; and large, 0.40 (Cohen, 1988).

441

442

443

444


445

446 **3. Results**

447

448 *3.1 Participants and safety*

449 Thirty-nine older men were randomised between October 2017 and February 2019: 36  
450 completed the study and 3 withdrew (see Fig. 2 for participant flow). Baseline characteristics  
451 of the 36 participants who completed the study are shown in Table 2. Resistance exercise  
452 was well tolerated, with only adverse event reported (muscle soreness), which resulted in one  
453 participant missing a single session. Following whey protein supplementation, renal function  
454 was not adversely affected, confirmed by an eGFR of  $>60$  mL/min/1.73m<sup>2</sup> in all participants  
455 following the intervention.



**Figure 2** Flow of participants throughout the study.

**Table 2** Baseline characteristics of participants<sup>1</sup>

	CON	PRO	EX+CON	EX+PRO	<i>P</i> value <sup>3</sup>	Overall
<i>n</i>	9	9	9	9	-	36
Age (y)	67 ± 2	66 ± 2	67 ± 1	68 ± 1	0.75	67 ± 1
Height (m)	1.77 ± 0.01	1.76 ± 0.03	1.77 ± 0.02	1.74 ± 0.03	0.71	1.76 ± 0.01
Body mass (kg)	79.0 ± 3.4	78.0 ± 3.1	78.2 ± 3.9	80.9 ± 4.0	0.94	79.0 ± 1.8
BMI (kg/m <sup>2</sup> )	25.1 ± 1.0	25.0 ± 0.6	25.1 ± 0.9	26.6 ± 0.8	0.50	25.5 ± 0.4
FFM (kg)	59.8 ± 1.5	60.0 ± 1.7	58.5 ± 2.6	60.5 ± 2.9	0.94	59.7 ± 1.1
SMM (kg)	26.7 ± 0.6	27.2 ± 0.7	25.9 ± 1.1	26.9 ± 1.3	0.79	26.7 ± 0.5
SMI (kg/m <sup>2</sup> )	8.5 ± 0.2	8.8 ± 0.2	8.3 ± 0.2	8.9 ± 0.3	0.19	8.6 ± 0.1
Fat mass (kg)	19.2 ± 2.4	18.0 ± 1.7	19.6 ± 2.0	20.4 ± 1.5	0.85	19.3 ± 0.3
Fat mass (%)	23.8 ± 2.0	22.7 ± 1.5	24.8 ± 1.7	25.1 ± 1.2	0.74	24.1 ± 0.8
Handgrip strength (kg)	41.8 ± 1.8	36.5 ± 2.5	39.9 ± 4.1	41.8 ± 2.1	0.37	40.1 ± 1.3
Leg extension 1RM (kg)	63 ± 6	58 ± 3	52 ± 5	59 ± 4	0.52	58 ± 2
Leg press 1RM (kg)	116 ± 9	107 ± 7	107 ± 9	118 ± 7	0.66	112 ± 4
SPPB (points)	11.7 ± 0.2	11.4 ± 0.2	11.2 ± 0.3	11.8 ± 0.1	0.38	11.5 ± 0.1
6MWT (m)	639 ± 21	616 ± 18	627 ± 30	591 ± 26	0.54	618 ± 12
4-m gait speed (m/s)	1.09 ± 0.08	1.13 ± 0.04	1.14 ± 0.04	1.22 ± 0.05	0.51	1.15 ± 0.03
Step count (steps/d)	10,766 ± 594	12,670 ± 1263	12,061 ± 1023	11,346 ± 907	0.55	11,710 ± 483
MVPA (min/d)	110 ± 8	127 ± 15	137 ± 18	135 ± 10	0.50	127 ± 7

<sup>1</sup>Values are means ± SE. <sup>3</sup>*P* value refers to differences between groups analysed by one-way ANOVA. No significant differences in baseline characteristics occurred between pooled exercise and non-exercise groups, or between pooled whey protein and control groups (data not shown). 1RM, one repetition maximum; 6MWT, 6-min walk test; BMI, body mass index; FFM, fat-free mass; MVPA, moderate-vigorous physical activity; SMI, skeletal muscle index; SMM, skeletal muscle mass; SPPB, short physical performance battery.

456 3.2 Exercise and supplement adherence

457 Participants in the EX+CON and EX+PRO groups attended  $98.2 \pm 1.0\%$  and  $98.2 \pm 1.2\%$  of  
458 their prescribed RE sessions, respectively ( $P = 0.63$ ,  $d = 0.00$ ). All participants completed their  
459 prescribed repetitions for sets 1 and 2 of each exercise. During the final set (to volitional  
460 failure), the mean number of completed repetitions was  $9.1 \pm 0.3$  in the EX+CON group and  
461  $9.1 \pm 0.2$  in the EX+PRO group ( $P = 0.97$ ,  $d = 0.00$ ). Compliance with the dietary supplements  
462 was  $94.1 \pm 1.2\%$ ,  $96.8 \pm 1.0\%$ ,  $96.1 \pm 1.3\%$ , and  $96.1 \pm 1.3\%$  in the CON, PRO, EX+CON and  
463 EX+PRO groups, respectively ( $P = 0.50$ ,  $f = 0.08$ ). Eighty percent of participants were unable  
464 to judge treatment allocation based on the supplement exit questionnaire.

465

466 3.3 Dietary intake

467 Significant group-by-time interactions were observed for total dietary protein intake (expressed  
468 as g/d, g/kg/d, and % energy;  $P < 0.001$ ,  $f = 1.45-1.70$ ), meal-specific relative protein intake  
469 (g/kg) at breakfast and lunch ( $P < 0.001$ ,  $f = 1.25-1.49$ ), and carbohydrate intake (expressed  
470 as g/d and % energy;  $P < 0.05$ ,  $f = 0.54-0.65$ ; Table 3). Total dietary protein intake increased  
471 over time in the PRO and EX+PRO groups greater than the CON and EX+CON groups at  
472 weeks 6 ( $P < 0.001$ ,  $d = 1.94-2.20$ ) and 12 ( $P < 0.001$ ,  $d = 2.19-2.39$ ). These increases were  
473 driven by increased intakes at breakfast and lunch ( $P < 0.001$ ,  $f = 2.18-2.84$ ). Carbohydrate  
474 intake increased over time in the EX+CON group greater than the PRO and EX+PRO groups  
475 at weeks 6 ( $P < 0.05$ ,  $d = 1.07-1.28$ ) and 12 ( $P < 0.05$ ,  $d = 1.02-1.09$ ). Total energy intake  
476 increased over time in the EX+PRO group at week 6 ( $P = 0.03$ ,  $d = 0.48$ ) and in the CON  
477 group at weeks 6 and 12 ( $P < 0.05$ ,  $d = 0.36-0.57$ ).

**Table 3** Dietary intake during the intervention period (including experimental supplements)<sup>1</sup>

	<u>Pooled</u>	<u>CON</u>		<u>PRO</u>		<u>EX+CON</u>		<u>EX+PRO</u>		<i>P</i> value <sup>2</sup>
	Baseline	6 weeks	12 weeks	6 weeks	12 weeks	6 weeks	12 weeks	6 weeks	12 weeks	
Energy (kcal/d) <sup>3</sup>	1964 ± 59	1944 ± 111 <sup>#</sup>	2013 ± 107 <sup>#</sup>	2055 ± 130	1937 ± 140	2177 ± 83	2176 ± 118	2238 ± 97 <sup>#</sup>	2159 ± 141	0.30
Protein (total)										
(g/d) <sup>3</sup>	81 ± 2	77 ± 5	74 ± 4	129 ± 4 <sup>*##</sup>	125 ± 5 <sup>*##</sup>	86 ± 4	82 ± 5	131 ± 6 <sup>*##</sup>	125 ± 3 <sup>*##</sup>	< 0.001
(g/kg/d) <sup>3</sup>	1.03 ± 0.02	0.97 ± 0.05	0.93 ± 0.03	1.64 ± 0.07 <sup>*##</sup>	1.60 ± 0.05 <sup>*##</sup>	1.10 ± 0.05	1.04 ± 0.07	1.63 ± 0.07 <sup>*##</sup>	1.58 ± 0.07 <sup>*##</sup>	< 0.001
(%)	16.8 ± 0.4	15.9 ± 0.7	15.1 ± 0.9	25.6 ± 1.3 <sup>*##</sup>	26.4 ± 1.4 <sup>*##</sup>	15.8 ± 0.7	15.2 ± 0.8	23.5 ± 0.6 <sup>*##</sup>	23.8 ± 1.4 <sup>*##</sup>	< 0.001
Protein (meal specific)										
Breakfast (g/kg) <sup>3</sup>	0.22 ± 0.02	0.23 ± 0.06	0.16 ± 0.03	0.54 ± 0.04 <sup>*##</sup>	0.51 ± 0.05 <sup>*##</sup>	0.22 ± 0.02	0.20 ± 0.02	0.52 ± 0.06 <sup>*##</sup>	0.50 ± 0.04 <sup>*##</sup>	< 0.001
Lunch (g/kg) <sup>3</sup>	0.28 ± 0.02	0.26 ± 0.05	0.22 ± 0.03	0.59 ± 0.03 <sup>*##</sup>	0.58 ± 0.05 <sup>*##</sup>	0.27 ± 0.04	0.28 ± 0.03	0.62 ± 0.03 <sup>*##</sup>	0.55 ± 0.04 <sup>*##</sup>	< 0.001
Dinner (g/kg) <sup>3</sup>	0.46 ± 0.02	0.45 ± 0.05	0.45 ± 0.05	0.57 ± 0.04	0.49 ± 0.04	0.48 ± 0.04	0.46 ± 0.07	0.43 ± 0.04	0.47 ± 0.02	0.41
Carbohydrate										
(g/d) <sup>3</sup>	232 ± 8	235 ± 11	250 ± 15	200 ± 21	209 ± 16	279 ± 16 <sup>‡\$#</sup>	280 ± 11 <sup>‡\$#</sup>	221 ± 11	238 ± 16	0.007
(%) <sup>3</sup>	48.5 ± 1.4	48.8 ± 3.6	49.9 ± 2.5	39.0 ± 3.6	43.1 ± 1.5	51.2 ± 2.0 <sup>‡\$</sup>	52.1 ± 2.2 <sup>‡\$#</sup>	39.7 ± 1.8	44.4 ± 2.1	0.03
Fat										
(g/d) <sup>3</sup>	68 ± 3	68 ± 5	71 ± 6	71 ± 10	55 ± 8	70 ± 5	68 ± 8	78 ± 5	62 ± 8	0.06
(%) <sup>3</sup>	31.0 ± 1.0	29.4 ± 1.3	31.4 ± 1.4 <sup>§</sup>	32.5 ± 1.7	25.3 ± 1.9	31.5 ± 2.5	27.6 ± 2.1	30.7 ± 2.2	25.3 ± 1.7	0.08

<sup>1</sup>Values are means ± SE. Baseline values for individual groups are not shown but no significant differences occurred between groups for any dietary marker. <sup>2</sup>*P* value refers to respective group-by-time interaction. <sup>3</sup>Significant main effect of time (*P* < 0.05). \*Significantly (*P* < 0.05) greater than CON group at respective time point. †Significantly greater than PRO group at respective time point. ‡Significantly greater than EX+CON group at respective time point. §Significantly greater than EX+PRO group at respective time point. #*P* < 0.05 from baseline value.

478 *3.4 Habitual physical activity*


479 No differences in daily step count ( $P = 0.61$ ,  $f = 0.24$ ), or time spent sedentary ( $P = 0.45$ ,  $f =$   
480  $0.30$ ), or in light ( $P = 0.67$ ,  $f = 0.22$ ) or MVPA ( $P = 0.80$ ,  $f = 0.21$ ) occurred between groups  
481 over time. No significant within-group differences occurred.

482

483 *3.5 Muscle strength*

484 Significant group-by-time interactions were observed for both leg extension ( $P < 0.001$ ,  $f =$   
485  $1.13$ ; Fig. 3A) and leg press 1RM ( $P < 0.001$ ,  $f = 1.76$ ; Fig. 3B). Both variables significantly  
486 increased over time in the EX+CON (+38%,  $P < 0.001$ ,  $d = 1.20$ ; +28%,  $P < 0.001$ ,  $d = 1.18$ ,  
487 respectively) and EX+PRO groups (+36%,  $P < 0.001$ ,  $d = 1.74$ ; +33%,  $P < 0.001$ ,  $d = 1.81$ ,  
488 respectively) greater than the CON and PRO groups ( $P < 0.001$ ,  $d = 1.50-1.90$ ). No differences  
489 were observed between either the CON and PRO groups ( $P > 0.98$ ;  $d = 0.11-0.31$ ), or the  
490 EX+CON and EX+PRO groups ( $P > 0.17$ ;  $d = 0.00-0.53$ ). When whey protein supplement  
491 groups were pooled, leg press 1RM did, however, tend to increase with a medium effect  
492 greater than control supplement groups pooled ( $P = 0.058$ ,  $f = 0.35$ ; Fig. 3C). No significant  
493 within- or between-group differences in handgrip strength occurred.





**Figure 3** Changes in (A) leg extension 1RM (kg) and (B) leg press 1RM (kg) between intervention groups (CON,  $n = 9$ ; PRO,  $n = 9$ ; EX+CON,  $n = 9$ ; EX+PRO,  $n = 9$ ); and (C) change in leg press 1RM (kg) between pooled whey protein ( $n = 18$ ) and control supplement groups ( $n = 18$ ). Data are presented as means  $\pm$  SE with circles representing individual data points. Analyses were performed using a mixed-model ANCOVA with baseline value only included as a covariate (panels A and B) and baseline value and exercise/non-exercise included as covariates (panel C). 1RM, one repetition maximum. \*Significantly ( $P < 0.05$ ) greater than CON group. †Significantly greater than PRO group.


494 3.6 *Body composition*

495 No significant within- or between-group differences occurred over time for skeletal muscle or  
496 FFM (Table 4); however, when exercise groups were pooled, FFM increased over time greater  
497 than non-exercise groups pooled ( $P = 0.045$ ,  $f = 0.37$ ; Fig. 4A). Fat mass and BMI significantly  
498 increased over time in the CON group ( $P < 0.05$ ,  $d = 0.07$ - $0.13$ ), and FM decreased, but not  
499 significantly, by  $-0.9 \pm 0.5$  kg ( $P = 0.09$ ,  $d = 0.20$ ) in the EX+PRO group. When expressed as  
500 a percentage, significant differences in FM over the course of the study were observed  
501 between the CON and EX+PRO groups ( $P = 0.03$ ,  $d = 0.67$ ). Also, when exercise groups were  
502 pooled, FM significantly decreased compared to non-exercise groups pooled ( $P = 0.048$ ,  $f =$   
503  $0.36$ ; Fig. 4B). In only the EX+PRO group, waist circumference significantly decreased over  
504 time ( $P = 0.01$ ,  $d = 0.12$ ).

**Table 4** Body composition outcomes for each treatment group at baseline and 12 weeks<sup>1</sup>

	<u>CON</u>		<u>PRO</u>		<u>EX+CON</u>		<u>EX+PRO</u>		Time	<u>P value</u> Group x time
	Baseline	12 weeks	Baseline	12 weeks	Baseline	12 weeks	Baseline	12 weeks		
Body mass (kg)	79.0 ± 3.4	79.8 ± 3.3 <sup>#</sup>	78.0 ± 3.1	78.3 ± 3.3	78.2 ± 3.9	79.0 ± 3.8	80.9 ± 4.0	81.0 ± 4.1	0.48	0.74
BMI (kg/m <sup>2</sup> )	25.1 ± 1.0	25.3 ± 0.9 <sup>#</sup>	25.0 ± 0.6	25.1 ± 0.7	25.1 ± 0.9	25.3 ± 0.9	26.6 ± 0.8	26.6 ± 0.8	0.45	0.80
FFM (kg)	59.8 ± 1.5	59.8 ± 1.6	60.0 ± 1.7	60.0 ± 1.9	58.5 ± 2.6	59.2 ± 2.5	60.5 ± 2.9	61.5 ± 2.9	0.92	0.23
SMM (kg)	26.7 ± 0.6	26.7 ± 0.7	27.2 ± 0.7	27.5 ± 0.8	25.9 ± 1.1	26.4 ± 1.1	26.9 ± 1.3	27.5 ± 1.3	0.99	0.35
SMI (kg/m <sup>2</sup> )	8.5 ± 0.2	8.5 ± 0.2	8.8 ± 0.2	8.9 ± 0.2	8.3 ± 0.2	8.4 ± 0.2	8.9 ± 0.3	9.1 ± 0.2	0.25	0.23
Fat mass (kg)	19.2 ± 2.4	20.1 ± 2.2 <sup>#</sup>	18.0 ± 1.7	18.3 ± 1.9	19.6 ± 2.0	19.8 ± 2.1	20.4 ± 1.5	19.5 ± 1.7	0.97	0.08
Fat mass (%)	23.8 ± 2.0	24.7 ± 1.9 <sup>#</sup> <sup>§</sup>	22.7 ± 1.5	22.9 ± 1.7	24.8 ± 1.7	24.6 ± 2.0	25.1 ± 1.2	23.8 ± 1.5	0.72	0.04
FMI (kg/m <sup>2</sup> )	6.1 ± 0.7	6.4 ± 0.7 <sup>#</sup>	5.7 ± 0.5	5.9 ± 0.6	6.3 ± 0.6	6.3 ± 0.6	6.7 ± 0.5	6.4 ± 0.5	0.89	0.07
Waist circumference (cm)	92.5 ± 2.6	92.8 ± 2.4	92.8 ± 3.0	93.1 ± 3.1	91.3 ± 3.5	91.7 ± 3.7	98.1 ± 3.4	97.0 ± 3.3 <sup>#</sup>	0.82	0.44
Waist:hip ratio	0.93 ± 0.02	0.92 ± 0.02	0.91 ± 0.02	0.91 ± 0.02	0.91 ± 0.02	0.91 ± 0.02	0.97 ± 0.02	0.96 ± 0.02	0.53	0.65

<sup>1</sup>Values are means ± SE. BMI, body mass index; FFM, fat-free mass; FMI, fat mass index; SMI, skeletal muscle index; SMM, skeletal muscle mass. <sup>§</sup>Significantly ( $P < 0.05$ ) greater than EX+PRO group. <sup>#</sup> $P < 0.05$  from baseline.




505

506 **Figure 4** Changes in (A) fat-free mass (kg) and (B) fat mass (kg) between pooled exercise ( $n$   
 507  $= 18$ ) and non-exercise groups ( $n = 18$ ) (means  $\pm$  SE). Circles represent individual data points.  
 508 Data were analysed by mixed-model ANCOVA with baseline value and supplement consumed  
 509 (whey protein or control) included as covariates.

510

### 511 3.7 Physical function

512 A significant group-by-time interaction was observed for 4-m gait speed ( $P = 0.043$ ,  $f = 0.54$ ;  
 513 Fig. 5A) but not SPPB ( $P = 0.84$ ,  $f = 0.17$ ) or 6MWT distance ( $P = 0.53$ ,  $f = 0.26$ ; Fig. 5B). In  
 514 the PRO group, gait speed increased by  $0.11 \pm 0.06$  m/s ( $d = 0.65$ ), which tended to increase  
 515 over time greater than the CON group ( $P = 0.06$ ,  $d = 0.64$ ). When whey protein supplement  
 516 groups were pooled, 4-m gait speed increased greater than control supplement groups pooled  
 517 ( $P = 0.007$ ,  $f = 0.51$ ; Fig. 5C). Significant within-group increases in 6MWT distance occurred  
 518 in both the EX+CON (+3.3%;  $P = 0.02$ ,  $d = 0.23$ ) and EX+PRO groups (+3.6%;  $P = 0.007$ ,  $d$   
 519  $= 0.28$ ). When RE groups were pooled, 6MWT distance increased greater than non-exercise  
 520 groups pooled ( $P = 0.04$ ,  $f = 0.39$ ; Fig. 5D). No significant within-group differences were  
 521 observed for the SPPB.




522

523 **Figure 5** Changes in (A) 4-m gait speed (m/s) and (B) 6MWT distance (m) between  
 524 intervention groups (CON,  $n = 9$ ; PRO,  $n = 9$ ; EX+CON,  $n = 9$ ; EX+PRO,  $n = 9$ ); (C) change  
 525 in 4-m gait speed (m/s) between pooled whey protein ( $n = 18$ ) and control supplement groups  
 526 ( $n = 18$ ); and (D) change in 6MWT distance (m) between pooled exercise ( $n = 18$ ) and non-  
 527 exercise groups ( $n = 18$ ). Data are presented as means  $\pm$  SE with circles representing  
 528 individual data points. Data were analysed using a mixed-model ANCOVA with baseline value  
 529 only included as a covariate (panels A and B), baseline value and exercise/non-exercise  
 530 included as covariates (panel C), and baseline value and supplement consumed (whey protein  
 531 or control) included as covariates (panel D). 6MWT, 6-min walk test. # $P < 0.05$  from baseline.

532 3.8 Hormonal and inflammatory biomarkers

533 Plasma insulin significantly decreased in only the EX+CON group (-13.9%;  $P = 0.04$ ,  $d = 0.31$ ),  
534 but no differences occurred between groups ( $P = 0.54$ ,  $f = 0.29$ ; Table 5). Plasma IL-6 and  
535 TNF- $\alpha$  significantly decreased over time in the EX+PRO group (-21%;  $P = 0.01$ ,  $d = 0.26$ ;  
536 -20%;  $P = 0.03$ ,  $d = 0.65$ , respectively). In the EX+CON group, similar but non-significant  
537 decreases were observed (-25%,  $P = 0.15$ ,  $d = 0.38$ ; -21%,  $P = 0.21$ ,  $d = 0.51$ , respectively).  
538 No differences occurred between groups for either variable ( $P = 0.13$ ,  $f = 0.46$ ;  $P = 0.11$ ,  $f =$   
539  $0.48$ , respectively); however, when RE groups were pooled, both IL-6 ( $P = 0.048$ ,  $f = 0.38$ ; Fig.  
540 6A) and TNF- $\alpha$  ( $P = 0.02$ ,  $f = 0.45$ ; Fig. 6B) significantly decreased over time greater than non-  
541 exercise groups pooled. Salivary cortisol slope increased in only the EX+PRO group (+91%;  
542  $P = 0.02$ ,  $d = 1.00$ ), which was driven by an increase in concentration upon waking (0650 h)  
543 (+84.9%;  $P = 0.06$ ,  $d = 0.84$ ). When whey protein supplement groups were pooled, awakening  
544 salivary cortisol concentration significantly increased greater than control supplement groups  
545 pooled ( $P = 0.049$ ,  $f = 0.37$ ; Fig. 7A). Serum myostatin concentration also significantly  
546 increased greater in the pooled whey protein compared to control supplement group ( $P = 0.01$ ,  
547  $f = 0.51$ ; Fig. 7B). No significant within- or between-group differences were observed for any  
548 other salivary cortisol index, or for plasma CRP, annexin A1 or IL-10, or serum IGF-1. No  
549 significant correlations were observed between changes in SMM, strength or physical function  
550 and any hormonal or inflammatory biomarker.



551


552 **Figure 6** Changes in fasting plasma (A) IL-6 (pg/mL) and (B) TNF- $\alpha$  (pg/mL) concentration  
 553 between pooled exercise ( $n = 17$ ) and non-exercise groups ( $n = 17$ ) (means  $\pm$  SE). Circles  
 554 represent individual data points. Data were analysed by mixed-model ANCOVA with baseline  
 555 value and supplement consumed (whey protein or control) included as covariates. IL-6,  
 556 interleukin-6; TNF- $\alpha$ , tumor necrosis factor-alpha.

**Table 5** Fasting hormonal and inflammatory biomarkers and salivary cortisol indices for each treatment group at baseline and 12 weeks<sup>1</sup>

	CON		PRO		EX+CON		EX+PRO		P value	
	Baseline	12 weeks	Baseline	12 weeks	Baseline	12 weeks	Baseline	12 weeks	Time	Group x time
Serum IGF-1 (ng/mL) <sup>2</sup>	152 ± 34	130 ± 29	119 ± 17	110 ± 14	137 ± 16	119 ± 12	118 ± 15	100 ± 10	0.07	0.86
Serum myostatin (ng/mL) <sup>3</sup>	2.2 ± 0.5	2.0 ± 0.4	1.9 ± 0.3	2.2 ± 0.3	1.8 ± 0.3	1.6 ± 0.1	2.3 ± 0.2	2.4 ± 0.3	0.06	0.15
Plasma insulin (mU/L) <sup>2</sup>	10.5 ± 1.6	10.5 ± 2.0	10.3 ± 1.5	8.9 ± 2.1	11.5 ± 2.9	9.9 ± 2.8 <sup>#</sup>	8.8 ± 1.8	6.7 ± 1.3	0.93	0.54
Plasma IL-6 (pg/mL) <sup>2</sup>	4.9 ± 1.2	5.8 ± 1.3	4.0 ± 1.0	4.0 ± 1.2	3.2 ± 0.9	2.4 ± 0.6	5.8 ± 1.8	4.6 ± 1.2 <sup>#</sup>	0.09	0.13
Plasma TNF- $\alpha$ (pg/mL) <sup>2</sup>	3.2 ± 0.3	3.0 ± 0.3	2.4 ± 0.3	3.0 ± 0.3	3.4 ± 0.6	2.7 ± 0.3	3.0 ± 0.4	2.4 ± 0.2 <sup>#</sup>	< 0.001	0.11
Plasma CRP (ng/mL) <sup>2</sup>	2.4 ± 0.6	1.7 ± 0.3	1.6 ± 0.4	1.1 ± 0.5	0.8 ± 0.2	0.8 ± 0.2	2.0 ± 0.4	1.8 ± 0.2	0.18	0.18
Plasma IL-10 (pg/mL) <sup>2</sup>	6.4 ± 0.8	7.0 ± 1.0	6.1 ± 0.7	5.7 ± 0.6	7.0 ± 1.4	6.1 ± 0.9	7.7 ± 0.9	7.0 ± 0.8	0.008	0.61
Plasma annexin A1 (pg/mL) <sup>2</sup>	444 ± 28	434 ± 29	447 ± 36	537 ± 127	561 ± 70	509 ± 51	568 ± 101	569 ± 101	0.33	0.71
Salivary cortisol (0650 h) (nmol/L) <sup>3</sup>	8.2 ± 1.6	9.4 ± 1.3	9.3 ± 1.5	14.8 ± 2.7	11.1 ± 1.7	13.0 ± 3.2	9.3 ± 1.9	17.2 ± 4.0	< 0.001	0.21
Salivary cortisol (2000 h) (nmol/L) <sup>3</sup>	2.1 ± 0.5	1.9 ± 0.5	1.9 ± 0.4	2.2 ± 0.6	2.2 ± 0.6	1.8 ± 0.7	2.1 ± 0.7	2.6 ± 0.6	0.009	0.64
Salivary cortisol AUC (nmol/L x 790 min) <sup>3</sup>	4067 ± 551	4349 ± 528	4088 ± 196	45450 ± 425	5588 ± 969	5326 ± 778	4127 ± 587	4530 ± 414	0.001	0.99
Salivary cortisol slope (nmol/L) <sup>3</sup>	9.6 ± 1.1	9.1 ± 1.4	10.6 ± 0.8	13.6 ± 2.4	12.5 ± 2.5	15.7 ± 2.7	8.8 ± 1.4	16.9 ± 3.5 <sup>#</sup>	0.004	0.15

<sup>1</sup>Values are means  $\pm$  SE. <sup>2</sup> $n = 34$  (CON,  $n = 8$ ; PRO,  $n = 9$ ; EX+CON,  $n = 8$ ; EX+PRO,  $n = 9$ ). <sup>3</sup> $n = 33$  (CON,  $n = 8$ ; PRO,  $n = 8$ ; EX+CON,  $n = 8$ ; EX+PRO,  $n = 9$ ). AUC, area under the curve; CRP, C-reactive protein; IGF-1, insulin-like growth factor 1; IL-6, interleukin-6; IL-10, interleukin-10; TNF- $\alpha$ , tumor necrosis factor-alpha. <sup>#</sup> $P < 0.05$  from baseline value.





557

558 **Figure 7** Changes in (A) 0650 h salivary cortisol (nmol/L) and (B) fasting serum myostatin  
 559 concentration (ng/mL) between pooled whey protein ( $n = 17$ ) and control supplement groups  
 560 ( $n = 16$ ) (means  $\pm$  SE). Circles represent individual data points. Awakening salivary cortisol  
 561 concentration data was analysed using the Scheirer-Ray-Hare two-way ANOVA of ranks test  
 562 with baseline rank and exercise or non-exercise included as covariates. Fasting serum  
 563 myostatin concentration data was analysed by mixed-model ANCOVA with baseline value and  
 564 exercise or non-exercise included as covariates.

565

#### 566 4. Discussion

567 To our knowledge, the present study is the first to investigate both the individual and combined  
 568 effects of RE and whey protein supplementation using recent recommendations for protein  
 569 dosing ( $>0.4$  g/kg/meal; 1.6 g/kg/d), employing a double-blind, placebo-controlled design, on  
 570 sarcopenia outcomes and hormonal and inflammatory biomarkers, including measurement of  
 571 diurnal salivary cortisol under highly controlled conditions, in healthy active older men. The  
 572 main findings were: i) RE significantly increased muscle strength, FFM and physical function,  
 573 and decreased markers of systemic inflammation and fat mass compared to non-exercise; ii)  
 574 whey protein supplementation significantly increased 4-m gait speed and increased muscle

575 strength (leg press 1RM) by a medium effect compared to an isocaloric carbohydrate control;  
576 however, increased awakening salivary cortisol and serum myostatin concentrations; iii) no  
577 synergistic effects occurred for any sarcopenia outcome compared to RE or whey protein  
578 supplementation alone; and iv) changes in sarcopenia outcomes did not correlate with  
579 changes in hormonal or inflammatory biomarkers.

580

581 Twelve weeks of progressive whole-body RE resulted in a combined mean increase in FFM  
582 of  $0.9 \pm 0.3$  kg (+1.2%), of which  $0.6 \pm 0.2$  kg (+2.3%) was estimated to be an increase in  
583 SMM. The magnitude of FFM increase is in line with previous studies that observed increases  
584 of ~1 kg following 12 weeks of RE in older adults (Campbell et al., 1995; Holwerda et al., 2018;  
585 Leenders et al., 2013; Verdijk et al., 2009). Accompanying the observed increase in FFM, the  
586 present study observed 36%, 31%, and 3.4% increases in leg extension and leg press 1RM,  
587 and 6MWT distance, respectively. These findings add to the current body of literature that  
588 have reported similar increases in muscle strength (Arnarson et al., 2013; Bell et al., 2017;  
589 Holwerda et al., 2018; Kirk et al., 2019; Leenders et al., 2013; Verdijk et al., 2009) and physical  
590 function as measured by the 6MWT following  $\geq 12$  weeks of RE training alone (Arnarson et al.,  
591 2013; Oesen et al., 2015) or combined with aerobic exercise in older adults (Bell et al., 2017;  
592 Kirk et al., 2019).

593

594 The present study observed a greater increase in 4-m gait speed and a medium, albeit non-  
595 significant effect towards a greater increase in muscle strength (leg press 1RM) following  
596 ingestion of whey protein supplementation compared to a carbohydrate control twice daily.  
597 These outcomes are in agreement with others that reported increases in muscle strength  
598 and/or physical function following increased dietary protein intake in older adults (Bauer et al.,  
599 2015; Bell et al., 2017; Kang et al., 2020; ten Haaf et al., 2019; Tieland et al., 2012b).  
600 Nevertheless, the novelty of data presented in the present compared to these studies is that  
601 protein supplementation, without additional nutrients known to stimulate hypertrophy and in  
602 healthy active non-sarcopenic older adults with habitual protein intakes  $>1.0$  g/kg/d, is an

603 effective strategy to improve physical function and mitigate sarcopenia. It is hypothesised that  
604 a more evenly distributed dietary protein intake produced by ingestion of whey protein  
605 supplementation at breakfast and lunch daily, which led to a protein intake of >0.4 g/kg/meal,  
606 the required dose to maximally stimulate rates of MPS in older adults (Moore et al., 2015),  
607 may partly explain these beneficial effects in this healthy active population. In support,  
608 previous cross-sectional studies have reported an association between evenly distributed  
609 dietary protein intake and increased muscle strength and physical function in older adults  
610 (Loenneke et al., 2016; ten Haaf et al., 2018). Whilst the effect of whey protein  
611 supplementation on muscle function was far inferior to that of RE (~10-30% of the effect of  
612 RE), as not all older adults are able or willing to perform RE (Dismore et al., 2020), these  
613 findings suggest that higher intakes of dietary protein, which is evenly distributed across the  
614 day, may be of clinical importance to attenuate age-related declines in these individuals.

615

616 Although whey protein supplementation aided muscle function, no effect was observed on  
617 skeletal muscle or FFM, which is in agreement with some (Björkman et al., 2020; Cramer et  
618 al., 2016; de Carvalho Bastone et al., 2020; Kim et al., 2012; Kirk et al., 2020; Kukuljan et al.,  
619 2009; Verreijen et al., 2017; Zhu et al., 2015) but not all previous studies (Bauer et al., 2015;  
620 Bell et al., 2017; Bo et al., 2019; Kang et al., 2020; Mitchell et al., 2017; Negro et al., 2019;  
621 Norton et al., 2016; ten Haaf et al., 2019). It has been suggested that disparities between  
622 previous studies may be explained by differences in the increase of dietary protein intake from  
623 baseline ( $\geq 0.4$  vs.  $< 0.4$  g/kg/d) (Park et al., 2018). However, the findings of this study oppose  
624 this hypothesis as dietary protein intake was increased by 0.6 g/kg/d. These data contrast  
625 others that increased dietary protein intake by 0.4-0.6 g/kg/d (Bell et al., 2017; Norton et al.,  
626 2016). Of note, the whey protein-based multi-ingredient supplement investigated by Bell and  
627 colleagues (2017) contained creatine, vitamin D and omega-3 polyunsaturated fatty acids, all  
628 of which have been shown to aid muscle hypertrophy (Devries and Phillips, 2014; Rosendahl-  
629 Riise et al., 2017; Smith et al., 2015). Also, the study by Norton et al. (2016) was double the  
630 duration of the present study, which might have provided a greater timeframe for protein-

631 induced increases in FFM. Therefore, inconsistencies between studies may be explained by  
632 differences in the instrumentation used to measure FFM, as most studies that report beneficial  
633 effects used dual x-ray absorptiometry (DXA), which is associated with less error than BIA  
634 (Achamrah et al., 2018).

635

636 This study tested the hypothesis that twice daily ingestion of a leucine-rich whey protein  
637 supplement would augment the effects of RE on SMM, strength and physical function. Despite  
638 gains in these outcomes following RE training alone and improved muscle function following  
639 whey protein supplementation, no augmented effects were observed. These findings are  
640 consistent with the majority (Arnarson et al., 2013; Candow et al., 2006; Chalé et al., 2013; de  
641 Carvalho Bastone et al., 2020; Dulac et al., 2020; Englund et al., 2018; Fielding et al., 2017;  
642 Gryson et al., 2014; Hofmann et al., 2016; Holm et al., 2008; Holwerda et al., 2018; Kim et al.,  
643 2012; Kirk et al., 2020, 2019; Krause et al., 2019; Kukuljan et al., 2009; Leenders et al., 2013;  
644 Maesta et al., 2007; Maltais et al., 2016; Oesen et al., 2015; Ottestad et al., 2017; Shahar et  
645 al., 2013; Thomson et al., 2016; Verdijk et al., 2009; Verreijen et al., 2017) but not all previous  
646 studies in older adults (Bell et al., 2017; Daly et al., 2014; Huschtscha et al., 2021; Junior et  
647 al., 2018; Kang et al., 2019; Rondanelli et al., 2020, 2016; Tieland et al., 2012b; Verreijen et  
648 al., 2015; Yamada et al., 2019; Zdzieblik et al., 2015). Similar to that of many studies that did  
649 not observe synergistic effects, the population used in this study were non-frail, i.e., displayed  
650 high baseline physical function scores, were physically active, and consumed sufficient but  
651 not optimal amounts of dietary protein at baseline according to consensus groups (Bauer et  
652 al., 2013; Deutz et al., 2014). In contrast, most studies that observed synergistic effects  
653 recruited sarcopenic or frail older adults, or, as previously highlighted, supplemented  
654 participants with multi-ingredient supplements (Bell et al., 2017; Kang et al., 2019; Rondanelli  
655 et al., 2020, 2016; Tieland et al., 2012c; Verreijen et al., 2015; Yamada et al., 2019; Zdzieblik  
656 et al., 2015). Nevertheless, the originality of the present study design adds a significant  
657 contribution to the literature that in healthy active older adults with a sufficient (~1 g/kg/d) but  
658 not optimal habitual protein intake, using recent recommendations for protein dosing (>0.4

659 g/kg/meal; 1.6 g/kg/d) without additional nutrients known to stimulate muscle hypertrophy is  
660 ineffective at augmenting RE-induced improvements in sarcopenia outcomes. However, it is  
661 important to note that as an effect of whey protein supplementation on muscle function when  
662 whey protein groups were pooled was observed in this study, the lack of synergistic effects  
663 may also be due to the present study being underpowered to detect post-hoc differences  
664 between the EX+CON and EX+PRO groups. For example, the post-hoc effect size for leg  
665 press 1RM ( $d = 0.53$ ) indicated 57 participants per group would have been required to  
666 determine a significant difference between the EX+CON and EX+PRO groups. Larger RCTs  
667 are therefore required to determine whether increased dietary protein intake in isolation [at a  
668 dose of  $\sim 1.6$  g/kg/d ( $>0.4$  g/kg/meal)] augments RE-induced effects in healthy older adults  
669 habitually consuming adequate amounts of dietary protein.

670

671 An interesting observation from the present study was the significant increase in awakening  
672 salivary cortisol and fasting plasma myostatin concentrations following termination of whey  
673 protein supplementation. Previously in this cohort, a significant increase in nocturnal protein  
674 oxidation and decreased protein balance have been reported following whey protein  
675 supplementation (Griffen, 2020). Together, these data indicate an increase in protein  
676 breakdown during the overnight fasting period, which has also been observed in older adults  
677 by others following termination of a high protein diet (Højfeldt et al., 2020). Glucocorticoids  
678 (e.g., the endogenous glucocorticoid cortisol) have been demonstrated to upregulate  
679 myostatin gene expression (Wang et al., 2016), an effect that may be mediated via  
680 glucocorticoid response elements in the promoter region of the myostatin gene (Qin et al.,  
681 2013). Furthermore, stress-induced catabolism by cortisol is thought to be myostatin  
682 dependent (Allen et al., 2010), suggesting a mechanistic link between cortisol concentration  
683 and regulation of myostatin. These novel findings highlight the importance of older individuals  
684 refraining from significantly reducing their dietary protein intake once commenced on a high  
685 protein diet to mitigate rises in nocturnal protein breakdown.

686

687 A key finding of this study was the significant reduction in markers of systemic inflammation  
688 following RE training. Age-related, low-grade systemic inflammation, termed inflammaging  
689 (Franceschi et al., 2006), is associated with numerous adverse health outcomes, including  
690 cardiovascular disease, insulin resistance, and higher mortality risk (Calder et al., 2017).  
691 Inflammation is also often cited in the aetiology of sarcopenia (Beyer et al., 2012). In the  
692 present study, the pro-inflammatory cytokines IL-6 and TNF- $\alpha$  decreased by ~20% following  
693 RE training alone and combined with whey protein supplementation. These findings are  
694 consistent with others (Bell et al., 2018; Rondanelli et al., 2016; Sardeli et al., 2018); however,  
695 these studies used multimodal exercise interventions (Bell et al., 2018), multi-ingredient  
696 supplements which contained nutrients with anti-inflammatory properties (Bell et al., 2018;  
697 Rondanelli et al., 2016), and only studies who employed a thrice weekly RE programme in the  
698 meta-analysis by Sardeli et al. (2018) reported reductions in markers of systemic  
699 inflammation. Consequently, the present data is original in that it highlights that as little as  
700 twice weekly RE performed at a high load either alone, or in combination with increased dietary  
701 protein intake without additional nutrients with known anti-inflammatory properties, is an  
702 effective strategy to offset inflammaging in healthy older adults.

703

704 Whilst RE decreased markers of systemic inflammation, changes in sarcopenia outcomes did  
705 not explain these reductions, which is in agreement with some (Hangelbroek et al., 2018) but  
706 not all studies (Grosicki et al., 2019). Instead, the changes seen may be explained in part by  
707 the differential change in fat mass observed between exercise and non-exercise groups.  
708 Specifically, the reduction in central adiposity observed in the EX+PRO group, which is a well-  
709 known causative factor of inflammaging (Beyer et al., 2012). In contrast to the effects on pro-  
710 inflammatory cytokines, RE did not alter concentrations of the anti-inflammatory markers IL-  
711 10 or annexin A1, suggesting the effects may be pro-inflammatory pathway specific. Thus,  
712 given that elevated IL-6 in particular is strongly associated with advancing age, morbidity and  
713 mortality (Beavers et al., 2010; Ershler, 1993), the findings of this study highlight the

714 importance of regular RE training in older age as a strategy to offset age-related increases in  
715 pro-inflammatory cytokines and to prolong healthy ageing.

716

717 The present study is only one of few that has investigated both the independent and combined  
718 effects of RE and increased dietary protein intake over a  $\geq 10$  week period on SMM, strength  
719 and physical function in older adults (de Carvalho Bastone et al., 2020; Gryson et al., 2014;  
720 Huschtscha et al., 2021; Kim et al., 2012; Kirk et al., 2020; Krause et al., 2019; Kukuljan et al.,  
721 2009; Maesta et al., 2007; Shahar et al., 2013; Verreijen et al., 2017). As such, the current  
722 research extends our understanding of this topic. In contrast to the above cited studies, the  
723 present study incorporated all of the following: i) a randomised, double-blind, placebo-  
724 controlled design; ii) the optimal dietary protein intake ( $>0.4$  g/kg/meal; 1.6 g/kg/d) to  
725 maximally augment RE-induced accretion of SMM (Moore et al., 2015; Morton et al., 2018);  
726 and iii) measurement of multiple hormonal and inflammatory biomarkers related to sarcopenia,  
727 including measurement of diurnal salivary cortisol under highly controlled conditions whilst  
728 participants resided in respiration chambers. These are novel aspects of this study. Limitations  
729 of this study include estimation of SMM using BIA, the small sample size per group and lack  
730 of statistical power to determine post-hoc differences between whey protein and control  
731 groups, inclusion of only men, and lack of familiarisation of physical function measures prior  
732 to baseline testing. The sample size is, however, coherent with a recently published  
733 exercise/protein 4-arm RCT in older adults (Huschtscha et al., 2021). Women were excluded  
734 based on reported sex differences in the magnitude of adaptation to RE previously reported  
735 in older adults (Da Boit et al., 2016). Nevertheless, as women account for a large proportion  
736 of older adults, future studies should address this aspect. Whilst a learning effect over time  
737 may have occurred for physical function measures that observed significant differences  
738 between pooled groups (i.e., 6MWT and 4-m gait speed), previous work has indicated no  
739 learning effect in older adults on these outcomes (Simonsick et al., 2000).

740

741

742 **5. Conclusion**

743 Twelve weeks of twice weekly RE significantly increased muscle strength, FFM and physical  
744 function and decreased circulating concentrations of pro-inflammatory biomarkers in healthy  
745 older men. Whey protein supplementation, which led to a protein intake of >0.4 g/kg/meal and  
746 1.6 g/kg/d, was ineffective at increasing skeletal muscle or FFM and increased awakening  
747 salivary cortisol and serum myostatin concentrations; however, led to a greater increase in 4-  
748 m gait speed and a medium effect towards a greater increase muscle strength (leg press 1RM)  
749 compared to control supplements pooled. Despite these increases following RE and whey  
750 protein supplementation independently, no synergistic effects were observed for any  
751 sarcopenia outcome. Finally, data from this study suggests that changes in sarcopenia  
752 outcomes are not related to changes in hormonal or inflammatory biomarkers.

753

754 **Acknowledgements**

755 We gratefully acknowledge the time and dedication of all participants who participated in this  
756 study. We thank Research Nurse Alison Campbell (University Hospitals Coventry and  
757 Warwickshire NHS Trust) and the nursing team for support in blood and saliva collection. The  
758 authors are also grateful to Yves Schellenberg from Agropur for providing the Instantized  
759 BiPRO whey protein supplement used in this study. This publication presents independent  
760 research jointly funded by University Hospitals Coventry and Warwickshire NHS Trust &  
761 Coventry University and carried out with support of the National Institute of Health Research  
762 (NIHR) Coventry and Warwickshire Clinical Research Facility. The views expressed are those  
763 of the author(s) and not necessarily those of University Hospitals Coventry and Warwickshire  
764 NHS Trust & Coventry University, the NIHR, or the Department of Health.

765

766 **Authors' Contributions**

767 CG designed the study, conducted data collection and analysed data, and wrote the  
768 manuscript; JH provided support in the design, conduct and analysis of the study and  
769 contributed to writing and critical review of the manuscript; DR provided support in the design



770 of the study, and contributed to writing and critical review of the manuscript; MD provided  
771 support in the design of the study, and contributed to writing and critical review of the  
772 manuscript; AD critically reviewed the manuscript; MOW served as primary clinical advisor  
773 and critically reviewed the manuscript. All authors have read and approved the final version  
774 of the manuscript and agree with the order of author presentation.

775

#### 776 **Competing Interests**

777 The whey protein supplement used in this study (Instantized BiPRO) was supplied by Agropur,  
778 Quebec, Canada. Agropur provided the supplement free of charge but had no involvement in  
779 data collection or analysis of this study. The authors declare no other conflicts of interest.

## References

- Achamrah, N., Colange, G., Delay, J., Rimbart, A., Folope, V., Petit, A., Grigioni, S., Déchelotte, P., Coëffier, M., 2018. Comparison of body composition assessment by DXA and BIA according to the body mass index: a retrospective study on 3655 measures. *PLoS One*. 13, e0200465. <https://doi.org/10.1371/journal.pone.0200465>
- Adam, E.K., Quinn, M.E., Tavernier, R., McQuillan, M.T., Dahlke, K.A., Gilbert, K.E., 2017. Diurnal cortisol slopes and mental and physical health outcomes: A systematic review and meta-analysis. *Psychoneuroendocrinology*. 83, 25-41. <https://doi.org/10.1016/j.psyneuen.2017.05.018>
- Allen, D.L., McCall, G.E., Loh, A.S., Madden, M.C., Mehan, R.S., 2010. Acute daily psychological stress causes increased atrophic gene expression and myostatin-dependent muscle atrophy. *Am. J. Physiol. Integr. Comp. Physiol.* 299, R889–R898. <https://doi.org/10.1152/ajpregu.00296.2010>
- Arnarson, A., Gudny Geirsdottir, O., Ramel, A., Briem, K., Jonsson, P. V., Thorsdottir, I., 2013. Effects of whey proteins and carbohydrates on the efficacy of resistance training in elderly people: Double blind, randomised controlled trial. *Eur. J. Clin. Nutr.* 67, 821–826. <https://doi.org/10.1038/ejcn.2013.40>
- Bagheri, R., Moghadam, Babak Hooshmand, Church, D.D., Tinsley, G.M., Eskandari, M., Moghadam, Bizhan Hooshmand, Motevalli, M.S., Baker, J.S., Robergs, R.A., Wong, A., 2020. The effects of concurrent training order on body composition and serum concentrations of follistatin, myostatin and GDF11 in sarcopenic elderly men. *Exp. Gerontol.* 133. <https://doi.org/10.1016/j.exger.2020.110869>
- Bagheri, R., Rashidlamir, A., Motevalli, M.S., Elliott, B.T., Mehrabani, J., Wong, A., 2019. Effects of upper-body, lower-body, or combined resistance training on the ratio of follistatin and myostatin in middle-aged men. *Eur. J. Appl. Physiol.* 119, 1921–1931. <https://doi.org/10.1007/s00421-019-04180-z>
- Bahat, G., Ilhan, B., 2016. Sarcopenia and the cardiometabolic syndrome: A narrative review. *Eur. Geriatr. Med.* 7, 220–223. <https://doi.org/10.1016/j.eurger.2015.12.012>

- Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A.J., Morley, J.E., Phillips, S., Sieber, C., Stehle, P., Teta, D., Visvanathan, R., Volpi, E., Boirie, Y., 2013. Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the prot-age study group. *J. Am. Med. Dir. Assoc.* 14, 542–559.  
<https://doi.org/10.1016/j.jamda.2013.05.021>
- Bauer, J.M., Verlaan, S., Bautmans, I., Brandt, K., Donini, L.M., Maggio, M., McMurdo, M.E.T., Mets, T., Seal, C., Wijers, S.L., Ceda, G.P., De Vito, G., Donders, G., Drey, M., Greig, C., Holmbäck, U., Narici, M., McPhee, J., Poggiogalle, E., Power, D., Scafoglieri, A., Schultz, R., Sieber, C.C., Cederholm, T., 2015. Effects of a Vitamin D and Leucine-Enriched Whey Protein Nutritional Supplement on Measures of Sarcopenia in Older Adults, the PROVIDE Study: A Randomized, Double-Blind, Placebo-Controlled Trial. *J. Am. Med. Dir. Assoc.* 16, 740–747. <https://doi.org/10.1016/j.jamda.2015.05.021>
- Beaudart, C., Zaaria, M., Pasleau, F., Reginster, J.Y., Bruyère, O., 2017. Health outcomes of sarcopenia: A systematic review and meta-analysis. *PLoS One* 12, e0169548.  
<https://doi.org/10.1371/journal.pone.0169548>
- Beavers, K.M., Hsu, F.C., Isom, S., Kritchevsky, S.B., Church, T., Goodpaster, B., Pahor, M., Nicklas, B.J., 2010. Long-term physical activity and inflammatory biomarkers in older adults. *Med. Sci. Sports Exerc.* 42, 2189–2196.  
<https://doi.org/10.1249/MSS.0b013e3181e3ac80>
- Bell, K.E., Snijders, T., Zulyniak, M., Kumbhare, D., Parise, G., Chabowski, A., Phillips, S.M., 2017. A whey protein-based multi-ingredient nutritional supplement stimulates gains in lean body mass and strength in healthy older men: A randomized controlled trial. *PLoS One* 12, e0181387. <https://doi.org/10.1371/journal.pone.0181387>
- Bell, K.E., Snijders, T., Zulyniak, M.A., Kumbhare, D., Parise, G., Chabowski, A., Phillips, S.M., 2018. A multi-ingredient nutritional supplement enhances exercise training-related reductions in markers of systemic inflammation in healthy older men. *Appl. Physiol. Nutr. Metab.* 43, 299–302. <https://doi.org/10.1139/apnm-2017-0533>
- Beyer, I., Mets, T., Bautmans, I., 2012. Chronic low-grade inflammation and age-related

sarcopenia. *Curr. Opin. Clin. Nutr. Metab. Care.* 15, 12-22.

<https://doi.org/10.1097/MCO.0b013e32834dd297>

Björkman, M.P., Suominen, M.H., Kautiainen, H., Jyväkorpi, S.K., Finne-Soveri, H.U.,

Strandberg, T.E., Pitkälä, K.H., Tilvis, R.S., 2020. Effect of Protein Supplementation on Physical Performance in Older People With Sarcopenia—A Randomized Controlled Trial. *J. Am. Med. Dir. Assoc.* 21, 226-232.e1.

<https://doi.org/10.1016/j.jamda.2019.09.006>

Bo, Y., Liu, C., Ji, Z., Yang, R., An, Q., Zhang, X., You, J., Duan, D., Sun, Y., Zhu, Y., Cui, H., Lu, Q., 2019. A high whey protein, vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults: A double-blind randomized controlled trial. *Clin. Nutr.* 38, 159-164. <https://doi.org/10.1016/j.clnu.2017.12.020>

Borde, R., Hortobágyi, T., Granacher, U., 2015. Dose–Response Relationships of Resistance Training in Healthy Old Adults: A Systematic Review and Meta-Analysis. *Sport. Med.* 45, 1693-1720. <https://doi.org/10.1007/s40279-015-0385-9>

Calder, P.C., Bosco, N., Bourdet-Sicard, R., Capuron, L., Delzenne, N., Doré, J., Franceschi, C., Lehtinen, M.J., Recker, T., Salvioli, S., Visioli, F., 2017. Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. *Ageing Res. Rev.* 40, 95-119.

<https://doi.org/10.1016/j.arr.2017.09.001>

Campbell, W.W., Crim, M.C., Young, V.R., Joseph, L.J., Evans, W.J., 1995. Effects of resistance training and dietary protein intake on protein metabolism in older adults. *Am. J. Physiol. - Endocrinol. Metab.* 268, E1143-E1153.

<https://doi.org/10.1152/ajpendo.1995.268.6.e1143>

Candow, D.G., Chilibeck, P.D., Facci, M., Abeysekara, S., Zello, G.A., 2006. Protein supplementation before and after resistance training in older men. *Eur. J. Appl. Physiol.* 97, 548-556. <https://doi.org/10.1007/s00421-006-0223-8>

Cermak, N.M., Res, P.T., De Groot, L.C.P.G.M., Saris, W.H.M., van Loon, L.J.C., 2012. Protein supplementation augments the adaptive response of skeletal muscle to

- resistance-type exercise training: A meta-analysis. *Am. J. Clin. Nutr.* 96, 1454-1464.  
<https://doi.org/10.3945/ajcn.112.037556>
- Chalé, A., Cloutier, G.J., Hau, C., Phillips, E.M., Dallal, G.E., Fielding, R.A., 2013. Efficacy of whey protein supplementation on resistance exercise-induced changes in lean mass, muscle strength, and physical function in mobility-limited older adults. *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* 68, 682–690.  
<https://doi.org/10.1093/gerona/gls221>
- Clark, B.C., Manini, T.M., 2008. Sarcopenia ≠ dynapenia. *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* 63, 829-834. <https://doi.org/10.1093/gerona/63.8.829>
- Coderre, L., Srivastava, A.K., Chiasson, J.-L., 1991. Role of glucocorticoid in the regulation of glycogen metabolism in skeletal muscle. *Am. J. Physiol. Metab.* 260, E927–E932.  
<https://doi.org/10.1152/ajpendo.1991.260.6.E927>
- Cohen, J., 1988. *Statistical power for the social sciences*. Hillsdale, NJ Laurence Erlbaum Assoc.
- Cramer, J.T., Cruz-Jentoft, A.J., Landi, F., Hickson, M., Zamboni, M., Pereira, S.L., Husted, D.S., Mustad, V.A., 2016. Impacts of High-Protein Oral Nutritional Supplements Among Malnourished Men and Women with Sarcopenia: A Multicenter, Randomized, Double-Blinded, Controlled Trial. *J. Am. Med. Dir. Assoc.* 17, 1044–1055.  
<https://doi.org/10.1016/j.jamda.2016.08.009>
- Crapo, R.O., Casaburi, R., Coates, A.L., Enright, P.L., MacIntyre, N.R., McKay, R.T., Johnson, D., Wanger, J.S., Zeballos, R.J., Bittner, V., Mottram, C., 2002. ATS statement: Guidelines for the six-minute walk test. *Am. J. Respir. Crit. Care Med.* 166,111-117. <https://doi.org/10.1164/ajrccm.166.1.at1102>
- Cruz-Jentoft, A.J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A.A., Schneider, S.M., Sieber, C.C., Topinkova, E., Vandewoude, M., Visser, M., Zamboni, M., Bautmans, I., Baeyens, J.P., Cesari, M., Cherubini, A., Kanis, J., Maggio, M., Martin, F., Michel, J.P., Pitkala, K., Reginster, J.Y., Rizzoli, R., Sánchez-Rodríguez, D., Schols, J., 2019. Sarcopenia: Revised European

consensus on definition and diagnosis. *Age Ageing*. 48, 16-31.

<https://doi.org/10.1093/ageing/afy169>

Da Boit, M., Sibson, R., Meakin, J.R., Aspden, R.M., Thies, F., Mangoni, A.A., Gray, S.R., 2016. Sex differences in the response to resistance exercise training in older people.

*Physiol. Rep.* 4, e12834. 6 <https://doi.org/10.14814/phy2.12834>

Daly, R.M., O'Connell, S.L., Mundell, N.L., Grimes, C.A., Dunstan, D.W., Nowson, C.A., 2014. Protein-enriched diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass and muscle strength and reduces circulating IL-6 concentrations in elderly women: a cluster randomized controlled trial.

*Am. J. Clin. Nutr.* 99, 899–910. <https://doi.org/10.3945/ajcn.113.064154>

Daly, R.M., Rosengren, B.E., Alwis, G., Ahlborg, H.G., Sernbo, I., Karlsson, M.K., 2013.

Gender specific age-related changes in bone density, muscle strength and functional performance in the elderly: A-10 year prospective population-based study. *BMC Geriatr.* 13, 1-9.

<https://doi.org/10.1186/1471-2318-13-71>

de Buyser, S.L., Petrovic, M., Taes, Y.E., Toye, K.R.C., Kaufman, J.M., Lapauw, B.,

Goemaere, S., 2016. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. *Age Ageing* 45, 603–609.

<https://doi.org/10.1093/ageing/afw071>

de Carvalho Bastone, A., Nobre, L.N., de Souza Moreira, B., Rosa, I.F., Ferreira, G.B.,

Santos, D.D.L., Monteiro, N.K.S.S., Alves, M.D., Gandra, R.A., de Lira, E.M., 2020.

Independent and combined effect of home-based progressive resistance training and nutritional supplementation on muscle strength, muscle mass and physical function in dynapenic older adults with low protein intake: A randomized controlled trial. *Arch. Gerontol. Geriatr.* 89, 104098.

<https://doi.org/10.1016/j.archger.2020.104098>

Deutz, N.E.P., Bauer, J.M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A.,

Cederholm, T., Cruz-Jentoft, A., Krznarić, Z., Nair, K.S., Singer, P., Teta, D., Tipton, K., Calder, P.C., 2014. Protein intake and exercise for optimal muscle function with aging: Recommendations from the ESPEN Expert Group. *Clin. Nutr.* 33, 929–936.

<https://doi.org/10.1016/j.clnu.2014.04.007>

Devries, M.C., Phillips, S.M., 2014. Creatine supplementation during resistance training in older adults-a meta-analysis. *Med. Sci. Sports. Exerc.* 46, 61194-61203. <https://doi.org/10.1249/MSS.0000000000000220>

Dismore, L., Hurst, C., Sayer, A., Stevenson, E., Aspray, T., Granic, A., 2020. Study of the older adults' motivators and barriers engaging in a nutrition and resistance exercise intervention for sarcopenia: An embedded qualitative project in the MilkMAN pilot study. *Gerontol. Geriatr. Med.* 6, 2333721420920398. <https://doi.org/10.1177/2333721420920398>

Dulac, M.C., Pion, C.H., Lemieux, F.C., Carvalho, L.P., El Hajj Boutros, G., Bélanger, M., Gaudreau, P., Chevalier, S., Morais, J.A., Noirez, P., Gouspillou, G., Aubertin-Leheudre, M., 2020. Effects of slow versus fast-digested protein supplementation combined with mixed power training on muscle function and functional capacities in older men. *Br. J. Nutr.* 125, 1017-1033. <https://doi.org/10.1017/S0007114520001932>

Englund, D.A., Kim, D.R., Koochek, A., Zhu, H., Trivison, T.G., Reid, K.F., Von Berens, Å., Melin, M., Cederholm, T., Gustafsson, T., Fielding, R.A., 2018. Nutritional supplementation with physical activity improves muscle composition in mobility-limited older adults, the VIVE2 study: A randomized, double-blind, placebo-controlled trial. *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* 73, 95-101. <https://doi.org/10.1093/gerona/glx141>

Ershler, W.B., 1993. Interleukin-6: A Cytokine for Gerontologists. *J. Am. Geriatr. Soc.* 41, 176–181. <https://doi.org/10.1111/j.1532-5415.1993.tb02054.x>

Esmarck, B., Andersen, J.L., Olsen, S., Richter, E.A., Mizuno, M., Kjaer, M., 2001. Timing of postexercise protein intake is important for muscle hypertrophy with resistance training in elderly humans. *J. Physiol.* 535, 301–311. <https://doi.org/10.1111/j.1469-7793.2001.00301.x>

Farsijani, S., Payette, H., Morais, J.A., Shatenstein, B., Gaudreau, P., Chevalier, S., 2017. Even mealtime distribution of protein intake is associated with greater muscle strength,

- but not with 3-y physical function decline, in free-living older adults: The Quebec longitudinal study on Nutrition as a Determinant of Successful Aging (NuAge study). *Am. J. Clin. Nutr.* 106, 113–124. <https://doi.org/10.3945/ajcn.116.146555>
- Fielding, R.A., Trivison, T.G., Kirn, D.R., Koochek, A., Reid, K.F., von Berens, Å., Zhu, H., Folta, S.C., Sacheck, J.M., Nelson, M.E., 2017. Effect of structured physical activity and nutritional supplementation on physical function in mobility-limited older adults: Results from the VIVE2 randomized trial. *J. Nutr. Health Aging* 21, 936–942. <https://doi.org/10.1007/s12603-017-0936-x>
- Finger, D., Goltz, F.R., Umpierre, D., Meyer, E., Rosa, L.H.T., Schneider, C.D., 2015. Effects of Protein Supplementation in Older Adults Undergoing Resistance Training: A Systematic Review and Meta-Analysis. *Sport. Med.* 45, 245-255 <https://doi.org/10.1007/s40279-014-0269-4>
- Foley, A.L., Hillier, S., Barnard, R., 2011. Effectiveness of once-weekly gym-based exercise programmes for older adults post discharge from day rehabilitation: A randomised controlled trial. *Br. J. Sports Med.* 45, 978–986. <https://doi.org/10.1136/bjism.2009.063966>
- Fragala, M.S., Cadore, E.L., Dorgo, S., Izquierdo, M., Kraemer, W.J., Peterson, M.D., Ryan, E.D., 2019. Resistance Training for Older Adults: Position Statement From the National Strength and Conditioning Association. *J. strength Cond. Res.* <https://doi.org/10.1519/JSC.0000000000003230>
- Franceschi, C., Bonafe, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., De Benedictis, G., 2006. Inflamm-aging: An Evolutionary Perspective on Immunosenescence. *Ann. N. Y. Acad. Sci.* 908, 244–254. <https://doi.org/10.1111/j.1749-6632.2000.tb06651.x>
- Freedson, P.S., Melanson, E., Sirard, J., 1998. Calibration of the Computer Science and Applications, Inc. accelerometer. *Med. Sci. Sports Exerc.* 30, 777–781. <https://doi.org/10.1097/00005768-199805000-00021>
- Grgic, J., Schoenfeld, B.J., Latella, C., 2019. Resistance training frequency and skeletal



muscle hypertrophy: A review of available evidence. *J. Sci. Med. Sport.* 22, 361-370.

<https://doi.org/10.1016/j.jsams.2018.09.223>

Griffen, C., 2020. Multidisciplinary research into the effects of resistance exercise and whey protein supplementation in healthy older men.

<https://pure.coventry.ac.uk/ws/portalfiles/portal/43661553/Griffen2021.pdf>

Grosicki, G.J., Barrett, B.B., Englund, D.A., Liu, C., Trivison, T.G., Cederholm, T., Koochek, A., Berens, Å. Von, Gustafsson, T., Benard, T., Reid, K.F., Fielding, R.A., 2019.

Circulating Interleukin-6 is Associated with Skeletal Muscle Strength, Quality, and Functional Adaptation with Exercise Training in Mobility-Limited Older Adults. *J. Frailty Aging* 1–7. <https://doi.org/10.14283/jfa.2019.30>

Gryson, C., Ratel, S., Rance, M., Penando, S., Bonhomme, C., Le Ruyet, P., Duclos, M., Boirie, Y., Walrand, S., 2014. Four-Month Course of Soluble Milk Proteins Interacts With Exercise to Improve Muscle Strength and Delay Fatigue in Elderly Participants. *J. Am. Med. Dir. Assoc.* 15, 958-e1. <https://doi.org/10.1016/j.jamda.2014.09.011>

Guralnik, J.M., Ferrucci, L., Pieper, C.F., Leveille, S.G., Markides, K.S., Ostir, G. V., Studenski, S., Berkman, L.F., Wallace, R.B., 2000. Lower extremity function and subsequent disability: Consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* 55, M221-M231. <https://doi.org/10.1093/gerona/55.4.M221>

Häkkinen, K., Kraemer, W.J., Pakarinen, A., Triplett-McBride, T., McBride, J.M., Häkkinen, A., Alen, M., McGuigan, M.R., Bronks, R., and Newton, R.U., 2002. Effects of Heavy Resistance/Power Training on Maximal Strength, Muscle Morphology, and Hormonal Response Patterns in 60-75-Year-Old Men and Women. *Can. J. App. Physiol.* 27, 213–231. <https://doi.org/10.1139/h02-013>

Hangelbroek, R.W.J., Knuijman, P., Tieland, M., de Groot, L.C., 2018. Attenuated strength gains during prolonged resistance exercise training in older adults with high inflammatory status. *Exp. Gerontol.* 106, 154–158.

<https://doi.org/10.1016/j.exger.2018.02.008>

- Hofmann, M., Schober-Halper, B., Oesen, S., Franzke, B., Tschan, H., Bachl, N., Strasser, E.M., Quittan, M., Wagner, K.H., Wessner, B., 2016. Effects of elastic band resistance training and nutritional supplementation on muscle quality and circulating muscle growth and degradation factors of institutionalized elderly women: the Vienna Active Ageing Study (VAAS). *Eur. J. Appl. Physiol.* 116, 885–897.  
<https://doi.org/10.1007/s00421-016-3344-8>
- Højfeldt, G., Bülow, J., Agergaard, J., Asmar, A., Schjerling, P., Simonsen, L., Bülow, J., van Hall, G. and Holm, L., 2020. Impact of habituated dietary protein intake on fasting and postprandial whole-body protein turnover and splanchnic amino acid metabolism in elderly men: a randomized, controlled, crossover trial. *Am. J. Clin. Nutr.* 112, 1468-1484. <https://doi.org/10.1093/ajcn/nqaa201>
- Holm, L., Olesen, J.L., Matsumoto, K., Doi, T., Mizuno, M., Alsted, T.J., Mackey, A.L., Schwarz, P., Kjær, M., 2008. Protein-containing nutrient supplementation following strength training enhances the effect on muscle mass, strength, and bone formation in postmenopausal women. *J. Appl. Physiol.* 105, 274-281.  
<https://doi.org/10.1152/jappphysiol.00935.2007>
- Holwerda, A.M., Overkamp, M., Paulussen, K.J.M., Smeets, J.S.J., van Kranenburg, J., Backx, E.M.P., Gijsen, A.P., Goessens, J.P.B., Verdijk, L.B., van Loon, L.J.C., 2018. Protein Supplementation after Exercise and before Sleep Does Not Further Augment Muscle Mass and Strength Gains during Resistance Exercise Training in Active Older Men. *J. Nutr.* 148, 1723–1732. <https://doi.org/10.1093/jn/nxy169>
- Hunter, G.R., Singh, H., Carter, S.J., Bryan, D.R., Fisher, G., 2019. Sarcopenia and Its Implications for Metabolic Health. *J. Obes.* <https://doi.org/10.1155/2019/8031705>
- Huschtscha, Z., Porter, J., Parr, A., Costa, R.J.S., 2021. The effects of a high protein dairy milk beverage with or without progressive resistance training on fat-free mass, skeletal muscle strength and power, and functional performance in healthy active older adults: A 12-week randomized controlled trial. *Front. Nutr.* 8, 644865.  
<https://doi.org/10.3389/fnut.2021.644865>

- Izquierdo, M., Häkkinen, K., Ibañez, J., Antón, A., Garrués, M., Ruesta, M., Gorostiaga, E.M., 2003. Effects of Strength Training on Submaximal and Maximal Endurance Performance Capacity in Middle-Aged and Older Men. *J. Strength. Cond. Res.* 17, 129–139.
- Janssen, I., 2010. Evolution of sarcopenia research. *Appl. Physiol. Nutr. Metab.* 35, 707–712. <https://doi.org/10.1139/H10-067>
- Janssen, I., Heymsfield, S.B., Baumgartner, R.N., Ross, R., 2000. Estimation of skeletal muscle mass by bioelectrical impedance analysis. *J. Appl. Physiol.* 89, 465–471. <https://doi.org/10.1152/jappl.2000.89.2.465>
- Jiang, Q., Lou, K., Hou, L., Lu, Y., Sun, L., Tan, S.C., Low, T.Y., Kord-Varkaneh, H., Pang, S., 2020. The effect of resistance training on serum insulin-like growth factor 1 (IGF-1): a systematic review and meta-analysis. *Complement. Ther. Med.* 102360. <https://doi.org/10.1016/j.ctim.2020.102360>
- Junior, P., Ribeiro, A., Nabuco, H., Fernandes, R., Tomeleri, C., Cunha, P., Venturini, D., Barbosa, D., Schoenfeld, B., Cyrino, E., 2018. Effects of whey protein supplementation associated with resistance training on muscular strength, hypertrophy, and muscle quality in preconditioned older women. *Int. J. Sport Nutr. Exerc. Metab.* 28, 528–535. <https://doi.org/10.1123/ijsnem.2017-0253>
- Kang, L., Gao, Y., Liu, X., Liang, Yinghui, Chen, Y., Liang, Yanhong, Zhang, L., Chen, W., Pang, H., Peng, L.-N., 2019. Effects of whey protein nutritional supplement on muscle function among community-dwelling frail older people: A multicenter study in China. *Arch. Gerontol. Geriatr.* 83, 7–12. <https://doi.org/10.1016/j.archger.2019.03.012>
- Kang, Y., Kim, N., Choi, Y.J., Lee, Y., Yun, J., Park, S.J., Park, H.S., Chung, Y.S., Park, Y.K., 2020. Leucine-enriched protein supplementation increases lean body mass in healthy Korean adults aged 50 years and older: A randomized, double-blind, placebo-controlled trial. *Nutrients.* 12, 1816. <https://doi.org/10.3390/nu12061816>
- Kim, H.K., Suzuki, T., Saito, K., Yoshida, H., Kobayashi, H., Kato, H., Katayama, M., 2012. Effects of exercise and amino acid supplementation on body composition and physical

- function in community-dwelling elderly Japanese sarcopenic women: A randomized controlled trial. *J. Am. Geriatr. Soc.* 60, 16–23. <https://doi.org/10.1111/j.1532-5415.2011.03776.x>
- Kirk, B., Mooney, K., Amirabdollahian, F., Khaiyat, O., 2019. Exercise and dietary-protein as a countermeasure to skeletal muscle weakness: Liverpool Hope University - Sarcopenia aging trial (LHU-SAT). *Front. Physiol.* 10, 445. <https://doi.org/10.3389/fphys.2019.00445>
- Kirk, B., Mooney, K., Cousins, R., Angell, P., Jackson, M., Pugh, J.N., Coyles, G., Amirabdollahian, F., Khaiyat, O., 2020. Effects of exercise and whey protein on muscle mass, fat mass, myoelectrical muscle fatigue and health-related quality of life in older adults: a secondary analysis of the Liverpool Hope University—Sarcopenia Ageing Trial (LHU-SAT). *Eur. J. Appl. Physiol.* 120, 493-503. <https://doi.org/10.1007/s00421-019-04293-5>
- Kirwan, R.P., Mazidi, M., García, C.R., Lane, K.E., Jafari, A., Butler, T., de Heredia, F.P., Davies, I.G., 2021. Protein interventions augment the effect of resistance exercise on appendicular lean mass and handgrip strength in older adults: a systematic review and meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* <https://doi.org/10.1093/ajcn/nqab355>
- Kneffel, Z., Murlasits, Z., Reed, J., Krieger, J., 2020. A meta-regression of the effects of resistance training frequency on muscular strength and hypertrophy in adults over 60 years of age. *J. Sports Sci.* 39, 351-358. <https://doi.org/10.1080/02640414.2020.1822595>
- Kraemer, W.J., Ratamess, N., Fry, A., French, D., 2006. Strength training: Development and evaluation of methodology, in: Maud, P, and Foster, C. (Eds.), *Physiological Assessment of Human Fitness, Human Kinetics*, 119–150.
- Kraemer, W.J., Ratamess, N.A., 2004. *Fundamentals of Resistance Training: Progression and Exercise Prescription. Med. Sci. Sports Exerc.* <https://doi.org/10.1249/01.MSS.0000121945.36635.61>

- Krause, M., Crognale, D., Cogan, K., Contarelli, S., Egan, B., Newsholme, P., De Vito, G., 2019. The effects of a combined bodyweight-based and elastic bands resistance training, with or without protein supplementation, on muscle mass, signaling and heat shock response in healthy older people. *Exp. Gerontol.* 115, 104–113.  
<https://doi.org/10.1016/j.exger.2018.12.004>
- Kukuljan, S., Nowson, C.A., Sanders, K., Daly, R.M., 2009. Effects of resistance exercise and fortified milk on skeletal muscle mass, muscle size, and functional performance in middle-aged and older men: An 18-mo randomized controlled trial. *J. Appl. Physiol.* 107, 1864-1873. <https://doi.org/10.1152/jappphysiol.00392.2009>
- Leenders, M., Verdijk, L.B., van Der Hoeven, L., van Kranenburg, J., Nilwik, R., Wodzig, W.K.W.H., Senden, J.M.G., Keizer, H.A., van Loon, L.J.C., 2013. Protein supplementation during resistance-type exercise training in the elderly. *Med. Sci. Sports Exerc.* 45, 542–552. <https://doi.org/10.1249/MSS.0b013e318272fcd8>
- Levey, A.S., Coresh, J., Greene, T., Stevens, L.A., Zhang, Y., Hendriksen, S., Kusek, J.W., van Lente, F., 2006. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann. Intern. Med.* 145, 247–254. <https://doi.org/10.7326/0003-4819-145-4-200608150-00004>
- Levinger, I., Goodman, C., Hare, D.L., Jerums, G., Toia, D., Selig, S., 2009. The reliability of the 1RM strength test for untrained middle-aged individuals. *J. Sci. Med. Sport* 12, 310–316. <https://doi.org/10.1016/j.jsams.2007.10.007>
- Liao, C. De, Tsauo, J.Y., Wu, Y.T., Cheng, C.P., Chen, Hui Chuen, Huang, Y.C., Chen, Hung Chou, Liou, T.H., 2017. Effects of protein supplementation combined with resistance exercise on body composition and physical function in older adults: A systematic review and meta-analysis. *Am. J. Clin. Nutr.* 106, 1078–1091.  
<https://doi.org/10.3945/ajcn.116.143594>
- Liberman, K., Njemini, R., Luiking, Y., Forti, L.N., Verlaan, S., Bauer, J.M., Memelink, R., Brandt, K., Donini, L.M., Maggio, M., Mets, T., Wijers, S.L.J., Sieber, C., Cederholm, T., Bautmans, I., 2019. Thirteen weeks of supplementation of vitamin D and leucine-

- enriched whey protein nutritional supplement attenuates chronic low-grade inflammation in sarcopenic older adults: the PROVIDE study. *Aging Clin. Exp. Res.* 31, 845–854. <https://doi.org/10.1007/s40520-019-01208-4>
- Loenneke, J.P., Loprinzi, P.D., Murphy, C.H., Phillips, S.M., 2016. Per meal dose and frequency of protein consumption is associated with lean mass and muscle performance. *Clin. Nutr.* 35, 1506–1511. <https://doi.org/10.1016/j.clnu.2016.04.002>
- Maesta, N., Nahas, E.A.P., Nahas-Neto, J., Orsatti, F.L., Fernandes, C.E., Traiman, P., Burini, R.C., 2007. Effects of soy protein and resistance exercise on body composition and blood lipids in postmenopausal women. *Maturitas* 56, 350–358. <https://doi.org/10.1016/j.maturitas.2006.10.001>
- Maltais, M.L., Ladouceur, J.P., Dionne, I.J., 2016. The Effect of Resistance Training and Different Sources of Postexercise Protein Supplementation on Muscle Mass and Physical Capacity in Sarcopenic Elderly Men. *J. Strength Cond. Res.* 30, 1680–1687. <https://doi.org/10.1519/JSC.0000000000001255>
- McKee, A., Morley, J.E., 2019. Hormones and sarcopenia. *Curr. Opin. Endocr. Metab. Res.* 9, 34-39. <https://doi.org/10.1016/j.coemr.2019.06.006>
- Mitchell, C.J., Milan, A.M., Mitchell, S.M., Zeng, N., Ramzan, F., Sharma, P., Knowles, S.O., Roy, N.C., Sjödín, A., Wagner, K.H., Cameron-Smith, D., 2017. The effects of dietary protein intake on appendicular lean mass and muscle function in elderly men: A 10-wk randomized controlled trial. *Am. J. Clin. Nutr.* 106, 1375-1383. <https://doi.org/10.3945/ajcn.117.160325>
- Moore, D.R., Churchward-Venne, T.A., Witard, O., Breen, L., Burd, N.A., Tipton, K.D., Phillips, S.M., 2015. Protein ingestion to stimulate myofibrillar protein synthesis requires greater relative protein intakes in healthy older versus younger men. *Journals Gerontol. - Ser. A Biol. Sci. Med. Sci.* 70, 57–62. <https://doi.org/10.1093/gerona/glu103>
- Morley, J.E., Argiles, J.M., Evans, W.J., Bhasin, S., Cella, D., Deutz, N.E.P., Doehner, W., Fearon, K.C.H., Ferrucci, L., Hellerstein, M.K., 2010. Nutritional recommendations for the management of sarcopenia. *J. Am. Med. Dir. Assoc.* 11, 391–396.

<https://doi.org/10.1016/j.jamda.2010.04.014>

- Morton, R.W., Murphy, K.T., McKellar, S.R., Schoenfeld, B.J., Henselmans, M., Helms, E., Aragon, A.A., Devries, M.C., Banfield, L., Krieger, J.W., Phillips, S.M., 2018. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults. *Br. J. Sports Med.* 52, 376–384. <https://doi.org/10.1136/bjsports-2017-097608>
- Negro, M., Perna, S., Spadaccini, D., Castelli, L., Calanni, L., Barbero, M., Cescon, C., Rondanelli, M., D'Antona, G., 2019. Effects of 12 Weeks of Essential Amino Acids (EAA)-Based Multi-Ingredient Nutritional Supplementation on Muscle Mass, Muscle Strength, Muscle Power and Fatigue in Healthy Elderly Subjects: A Randomized Controlled Double-Blind Study. *J. Nutr. Heal. Aging* 23, 414–424. <https://doi.org/10.1007/s12603-019-1163-4>
- Norton, C., Toomey, C., McCormack, W.G., Francis, P., Saunders, J., Kerin, E., Jakeman, P., 2016. Protein supplementation at breakfast and lunch for 24 weeks beyond habitual intakes increases whole-body lean tissue mass in healthy older adults. *J. Nutr.* 146, 65–69. <https://doi.org/10.3945/jn.115.219022>
- Oesen, S., Halper, B., Hofmann, M., Jandrasits, W., Franzke, B., Strasser, E.M., Graf, A., Tschan, H., Bachl, N., Quittan, M., Wagner, K.H., Wessner, B., 2015. Effects of elastic band resistance training and nutritional supplementation on physical performance of institutionalised elderly - A randomized controlled trial. *Exp. Gerontol.* 72, 99–108. <https://doi.org/10.1016/j.exger.2015.08.013>
- Ottestad, I., Løvstad, A.T., Gjevestad, G.O., Hamarsland, H., Šaltytė Benth, J., Andersen, L.F., Bye, A., Biong, A.S., Retterstøl, K., Iversen, P.O., Raastad, T., Ulven, S.M., Holven, K.B., 2017. Intake of a protein-enriched milk and effects on muscle mass and strength. A 12-week randomized placebo controlled trial among community-dwelling older adults. *J. Nutr. Heal. Aging.* 21, 1160-1169. <https://doi.org/10.1007/s12603-016-0856-1>

- Park, Y., Choi, J.E., Hwang, H.S., 2018. Protein supplementation improves muscle mass and physical performance in undernourished prefrail and frail elderly subjects: A randomized, double-blind, placebo-controlled trial. *Am. J. Clin. Nutr.* 108, 1026–1033. <https://doi.org/10.1093/ajcn/nqy214>
- Park, Y., Park, H.-Y., Kim, J., Hwang, H., Jung, Y., Kreider, R., and Lim, K., 2019. Effects of Whey Protein Supplementation Prior to, and Following, Resistance Exercise on Body Composition and Training Responses: A Randomized Double-Blind Placebo-Controlled Study. *J. Ex. Nutr. Biochem.* 23, 34. <https://doi.org/10.20463/jenb.2019.0015>
- Peterson, M.D., Rhea, M.R., Sen, A., Gordon, P.M., 2010. Resistance exercise for muscular strength in older adults: A meta-analysis. *Ageing Res. Rev.* 9, 226-237. <https://doi.org/10.1016/j.arr.2010.03.004>
- Peterson, M.D., Sen, A., Gordon, P.M., 2011. Influence of resistance exercise on lean body mass in aging adults: A meta-analysis. *Med. Sci. Sports Exerc.* 43, 249. <https://doi.org/10.1249/MSS.0b013e3181eb6265>
- Phillips, S.M., Chevalier, S., Leidy, H.J., 2016. Protein “requirements” beyond the RDA: implications for optimizing health. *Appl. Physiol. Nutr. Metab.* <https://doi.org/10.1139/apnm-2015-0550>
- Phillips, W.T., Batterham, A.M., Valenzuela, J.E., Burkett, L.N., 2004. Reliability of Maximal Strength Testing in Older Adults. *Arch. Phys. Med. Rehabil.* 85, 329–334. <https://doi.org/10.1016/j.apmr.2003.05.010>
- Pinedo-Villanueva, R., Westbury, L.D., Syddall, H.E., Sanchez-Santos, M.T., Dennison, E.M., Robinson, S.M., Cooper, C., 2019. Health Care Costs Associated With Muscle Weakness: A UK Population-Based Estimate. *Calcif. Tissue Int.* 104, 137–144. <https://doi.org/10.1007/s00223-018-0478-1>
- Qin, J., Du, R., Yang, Y.-Q., Zhang, H.-Q., Li, Q., Liu, L., Guan, H., Hou, J., An, X.-R., 2013. Dexamethasone-induced skeletal muscle atrophy was associated with upregulation of myostatin promoter activity. *Res. Vet. Sci.* 94, 84–89. <https://doi.org/10.1016/j.rvsc.2012.07.018>



- Reginster, J.Y., Cooper, C., Rizzoli, R., Kanis, J.A., Appelboom, G., Bautmans, I., Bischoff-Ferrari, H.A., Boers, M., Brandi, M.L., Bruyère, O., Cherubini, A., Flamion, B., Fielding, R.A., Gasparik, A.I., Van Loon, L., McCloskey, E., Mitlak, B.H., Pilotto, A., Reiter-Niesert, S., Rolland, Y., Tsouderos, Y., Visser, M., Cruz-Jentoft, A.J., 2016. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. *Aging Clin. Exp. Res.* <https://doi.org/10.1007/s40520-015-0517-y>
- Roberts, H.C., Denison, H.J., Martin, H.J., Patel, H.P., Syddall, H., Cooper, C., Sayer, A.A., 2011. A review of the measurement of grip strength in clinical and epidemiological studies: Towards a standardised approach. *Age Ageing*. 40, 423-429. <https://doi.org/10.1093/ageing/afr051>
- Rondanelli, M., Cereda, E., Klersy, C., Faliva, M.A., Peroni, G., Nichetti, M., Gasparri, C., Iannello, G., Spadaccini, D., Infantino, V., 2020. Improving rehabilitation in sarcopenia: a randomized-controlled trial utilizing a muscle-targeted food for special medical purposes. *J. Cachexia. Sarcopenia Muscle*.11, 1535-1547. <https://doi.org/10.1002/jcsm.12532>
- Rondanelli, M., Klersy, C., Terracol, G., Talluri, J., Maugeri, R., Guido, D., Faliva, M.A., Solerte, B.S., Fioravanti, M., Lukaski, H., Perna, S., 2016. Whey protein, amino acids, and Vitamin D supplementation with physical activity increases fat-free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly. *Am. J. Clin. Nutr.* 103, 830–840. <https://doi.org/10.3945/ajcn.115.113357>
- Rosendahl-Riise, H., Spielau, U., Ranhoff, A.H., Gudbrandsen, O.A., Dierkes, J., 2017. Vitamin D supplementation and its influence on muscle strength and mobility in community-dwelling older persons: a systematic review and meta-analysis. *J. Hum. Nutr. Diet.* 30, 3–15. <https://doi.org/10.1111/jhn.12394>
- Sardeli, A.V., Tomeleri, C.M., Cyrino, E.S., Fernhall, B., Cavaglieri, C.R., Chacon-Mikahil, M.P.T., 2018. Effect of resistance training on inflammatory markers of older adults: A meta-analysis. *Exp. Gerontol.* 111, 188-196. <https://doi.org/10.1016/j.exger.2018.07.021>

- Sawilowsky, S.S., 2009. New Effect Size Rules of Thumb. *J. Mod. Appl. Stat. Methods*.  
<https://doi.org/10.22237/jmasm/1257035100>
- Schoenfeld, B.J., 2012. Does exercise-induced muscle damage play a role in skeletal muscle hypertrophy? *J. Strength Cond. Res.* 26, 1441–1453.  
<https://doi.org/10.1519/JSC.0b013e31824f207e>
- Schulz, K.F., Altman, D.G., Moher, D., 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *Trials* 11, 1–8.  
<https://doi.org/10.1186/1741-7015-8-18>
- Shahar, S., Kamaruddin, N.S., Badrasawi, M., Mohamed Sakian, N.I., Manaf, Z.A., Yassin, Z., Joseph, L., 2013. Effectiveness of exercise and protein supplementation intervention on body composition, functional fitness, and oxidative stress among elderly Malays with sarcopenia. *Clin. Interv. Aging* 8, 1365–1375. <https://doi.org/10.2147/CIA.S46826>
- Silva, R.G. da, Silva, D.R.P. da, Pina, F.L.C., Nascimento, M.A. do, Ribeiro, A.S., Cyrino, E.S., 2017. Effect of two different weekly resistance training frequencies on muscle strength and blood pressure in normotensive older women. *Rev. Bras. Cineantropometria Desempenho Hum.* 19, 118–127. <https://doi.org/10.5007/1980-0037.2017v19n1p118>
- Simmons, P.S., Miles, J.M., Gerich, J.E., Haymond, M.W., 1984. Increased proteolysis. An effect of increases in plasma cortisol within the physiologic range. *J. Clin. Invest.* 73, 412–420. <https://doi.org/10.1172/JCI111227>
- Simonsick, E.M., Gardner, A.W. and Poehlman, E.T., 2000. Assessment of physical function and exercise tolerance in older adults: reproducibility and comparability of five measures. *Aging. Clin. Exp. Res.* 12, 274-280. <https://doi.org/10.1007/BF03339847>
- Smeuninx, B., Greig, C.A., Breen, L., 2020. Amount, Source and Pattern of Dietary Protein Intake Across the Adult Lifespan: A Cross-Sectional Study. *Front. Nutr.* 7, 25.  
<https://doi.org/10.3389/fnut.2020.00025>
- Smith, G.I., Julliand, S., Reeds, D.N., Sinacore, D.R., Klein, S., Mittendorfer, B., 2015. Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older

- adults. *Am. J. Clin. Nutr.* 102, 115–122. <https://doi.org/10.3945/ajcn.114.105833>
- Stec, M.J., Thalacker-Mercer, A., Mayhew, D.L., Kelly, N.A., Tuggle, C.S., Merritt, E.K., Brown, C.J., Windham, S.T., Dell'Italia, L.J., Bickel, S.C., Roberts, B.M., Vaughn, K.M., Isakova-Donahue, I., Many, G.M., Bamman, M.M., 2017. Randomized, four-arm, dose-response clinical trial to optimize resistance exercise training for older adults with age-related muscle atrophy. *Exp. Gerontol.* 99, 98-109. <https://doi.org/10.1016/j.exger.2017.09.018>
- Steib, S., Schoene, D., Pfeifer, K., 2010. Dose-response relationship of resistance training in older adults: A meta-analysis. *Med. Sci. Sports Exerc.* 42, 902–914. <https://doi.org/10.1249/MSS.0b013e3181c34465>
- ten Haaf, D.S.M., Eijsvogels, T.M.H., Bongers, C.C.W.G., Horstman, A.M.H., Timmers, S., de Groot, L.C.P.G.M., Hopman, M.T.E., 2019. Protein supplementation improves lean body mass in physically active older adults: a randomized placebo-controlled trial. *J. Cachexia. Sarcopenia Muscle.* 10, 298-310. <https://doi.org/10.1002/jcsm.12394>
- ten Haaf, D.S.M., van Dongen, E.J.I., Nuijten, M.A.H., Eijsvogels, T.M.H., De Groot, L.C., Hopman, M.T.E., 2018. Protein intake and distribution in relation to physical functioning and quality of life in community-dwelling elderly people: Acknowledging the role of physical activity. *Nutrients* 10, 506. <https://doi.org/10.3390/nu10040506>
- Thomson, R.L., Brinkworth, G.D., Noakes, M., Buckley, J.D., 2016. Muscle strength gains during resistance exercise training are attenuated with soy compared with dairy or usual protein intake in older adults: A randomized controlled trial. *Clin. Nutr.* 35, 27-33. <https://doi.org/10.1016/j.clnu.2015.01.018>
- Tieland, M., Borgonjen-Van Den Berg, K.J., van Loon, L.J.C., De Groot, L.C.P.G.M., 2012a. Dietary protein intake in community-dwelling, frail, and institutionalized elderly people: Scope for improvement. *Eur. J. Nutr.* 51, 173–179. <https://doi.org/10.1007/s00394-011-0203-6>
- Tieland, M., Dirks, M.L., van der Zwaluw, N., Verdijk, L.B., van de Rest, O., de Groot, L.C.P.G.M., van Loon, L.J.C., 2012b. Protein Supplementation Increases Muscle Mass

- Gain During Prolonged Resistance-Type Exercise Training in Frail Elderly People: A Randomized, Double-Blind, Placebo-Controlled Trial. *J. Am. Med. Dir. Assoc.* 13, 713–719. <https://doi.org/10.1016/j.jamda.2012.05.020>
- Verdijk, L.B., Jonkers, R.A.M., Gleeson, B.G., Beelen, M., Meijer, K., Savelberg, H.H.C.M., Wodzig, K.W.H.W., Dendale, P., van Loon, L.J.C., 2009. Protein supplementation before and after exercise does not further augment skeletal muscle hypertrophy after resistance training in elderly men. *Am. J. Clin. Nutr.* 89, 608–616. <https://doi.org/10.3945/ajcn.2008.26626>
- Verreijen, A.M., Engberink, M.F., Memelink, R.G., van der Plas, S.E., Visser, M., Weijs, P.J.M., 2017. Effect of a high protein diet and/or resistance exercise on the preservation of fat free mass during weight loss in overweight and obese older adults: a randomized controlled trial. *Nutr. J.* 16, 1–8. <https://doi.org/10.1186/s12937-017-0229-6>
- Verreijen, A.M., Verlaan, S., Engberink, M.F., Swinkels, S., de Vogel-van den Bosch, J., Weijs, P.J.M., 2015. A high whey protein-, leucine-, and vitamin D-enriched supplement preserves muscle mass during intentional weight loss in obese older adults: a double-blind randomized controlled trial. *Am. J. Clin. Nutr.* 101, 279–286. <https://doi.org/10.3945/ajcn.114.090290>
- Wang, R., Jiao, H., Zhao, J., Wang, X., Lin, H., 2016. Glucocorticoids enhance muscle proteolysis through a myostatin-dependent pathway at the early stage. *PLoS One* 11, e0156225. <https://doi.org/10.1371/journal.pone.0156225>
- White, T.A., Lebrasseur, N.K., 2014. Myostatin and sarcopenia: Opportunities and challenges - A mini-review. *Gerontology.* 60, 289-293. <https://doi.org/10.1159/000356740>
- Yamada, M., Kimura, Y., Ishiyama, D., Nishio, N., Otobe, Y., Tanaka, T., Ohji, S., Koyama, S., Sato, A., Suzuki, M., 2019. Synergistic effect of bodyweight resistance exercise and protein supplementation on skeletal muscle in sarcopenic or dynapenic older adults. *Geriatr. Gerontol. Int.* 19, 429–437. <https://doi.org/10.1111/ggi.13643>
- Yoshimura, Y., Wakabayashi, H., Yamada, M., Kim, H., Harada, A., Arai, H., 2017.

Interventions for Treating Sarcopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. *J. Am. Med. Dir. Assoc.* 18, 553-e1.

<https://doi.org/10.1016/j.jamda.2017.03.019>

Zdzieblik, D., Oesser, S., Baumstark, M.W., Gollhofer, A., König, D., 2015. Collagen peptide supplementation in combination with resistance training improves body composition and increases muscle strength in elderly sarcopenic men: a randomised controlled trial.

*Br. J. Nutr.* 114, 1237–1245. <https://doi.org/10.1017/S0007114515002810>

Zhu, K., Kerr, D.A., Meng, X., Devine, A., Solah, V., Binns, C.W., Prince, R.L., 2015. Two-Year Whey Protein Supplementation Did Not Enhance Muscle Mass and Physical Function in Well-Nourished Healthy Older Postmenopausal Women. *J. Nutr.* 145,

2520–2526. <https://doi.org/10.3945/jn.115.218297>